

1 Title: Projecting vaccine demand and impact for emerging zoonotic pathogens

2

3 Authors: A Lerch<sup>1</sup>, QA ten Bosch<sup>2</sup>, M L'Azou Jackson<sup>3</sup>, AA Bettis<sup>4</sup>, M Bernuzzi<sup>3</sup>, GAV  
4 Murphy<sup>5</sup>, QM Tran<sup>1</sup>, JH Huber<sup>1</sup>, AS Siraj<sup>1</sup>, GM Bron<sup>2</sup>, M Elliott<sup>1</sup>, CS Hartlage<sup>1</sup>, K Koh<sup>1</sup>,  
5 K Strimbu<sup>1</sup>, M Walters<sup>1</sup>, TA Perkins<sup>1\*</sup>, SM Moore<sup>1\*</sup>

6

7 <sup>1</sup>Department of Biological Sciences and Eck Institute for Global Health, University of  
8 Notre Dame, Notre Dame, Indiana, USA

9

10 <sup>2</sup>Quantitative Veterinary Epidemiology, Wageningen University and Research,  
11 Wageningen, Netherlands

12

13 <sup>3</sup>Coalition for Epidemic Preparedness Innovations (CEPI), London, UK

14

15 <sup>4</sup>Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway

16

17 <sup>5</sup>Bill & Melinda Gates Foundation, Seattle, Washington, USA

18

19

20 \*Corresponding authors:

21 T Alex Perkins, [taperkins@nd.edu](mailto:taperkins@nd.edu)

22 Sean M Moore, [smoore15@nd.edu](mailto:smoore15@nd.edu)

23

## 24 **Abstract**

25  
26 Despite large outbreaks in humans seeming improbable for a number of zoonotic pathogens,  
27 several pose a concern due to their epidemiological characteristics and evolutionary potential.  
28 To enable effective responses to these pathogens in the event that they undergo future  
29 emergence, the Coalition for Epidemic Preparedness Innovations is advancing the development  
30 of vaccines for several pathogens prioritized by the World Health Organization. A major  
31 challenge in this pursuit is anticipating demand for a vaccine stockpile to support outbreak  
32 response. We developed a modeling framework for outbreak response for emerging zoonoses  
33 under three reactive vaccination strategies. Annual vaccine regimen requirements for a  
34 population-wide strategy ranged from >670,000 (95% prediction interval: 0-3,630,000) regimens  
35 for Lassa virus to 1,190,000 (95% Pri: 0-8,480,000) regimens for Rift Valley fever virus, while  
36 the regimens required for ring vaccination or targeting healthcare workers (HCWs) were several  
37 orders of magnitude lower (between 1/25 and 1/700) than those required by a population-wide  
38 strategy. For each pathogen and vaccination strategy, reactive vaccination typically prevented  
39 fewer than 10% of cases, because of their presently low  $R_0$  values. Targeting HCWs had a  
40 higher per-regimen impact than population-wide vaccination. Our framework provides a flexible  
41 methodology for estimating vaccine stockpile needs and the geographic distribution of demand  
42 under a range of outbreak response scenarios.

## 43 44 **Introduction**

45 Less than two years ago, SARS-CoV-2 was an unknown virus circulating in a zoonotic reservoir  
46 (Andersen et al. 2020). In the time since, it has caused a pandemic resulting in more than 4.6  
47 million deaths (WHO 2020). Theoretical work (Antia et al. 2003) predicts that frequent small-  
48 scale outbreaks in humans may provide opportunities for selection of more transmissible  
49 variants that facilitate emergence from the original reservoir. Indeed, virological studies indicate  
50 that a sequence of mutations acquired in this manner may offer a plausible explanation for the  
51 emergence of SARS-CoV in 2003 (Sheahan et al. 2008). More frequent spillover and more  
52 human-to-human transmission ensuing from those spillovers are expected to increase the  
53 probability that adaptations such as these arise and facilitate more widespread emergence  
54 (Morse et al. 2012). Because of this evolutionary potential, even zoonotic pathogens with limited  
55 human-to-human transmission—as defined by a basic reproduction number,  $R_0$ , below 1—are  
56 viewed as a concern. The status quo of investing in the development of diagnostics,  
57 therapeutics, and vaccines only in reaction to emerging disease threats has made the world  
58 dangerously vulnerable to pandemics (Røttingen et al. 2017; Excler et al. 2021).


59 To preempt future public health emergencies arising from emerging zoonotic diseases, the  
60 World Health Organization (WHO) developed a research and development blueprint for action  
61 to prevent epidemics (WHO 2016). This R&D Blueprint prioritizes and regularly updates a list of  
62 pathogens for development of diagnostics, therapeutics, and vaccines  
63 ([https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)  
64 [emergency-contexts](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)). The Coalition for Epidemic Preparedness Innovations (CEPI) was  
65 launched in 2017 to accelerate the development of vaccines against emerging infectious  
66 diseases and to enable equitable access to these vaccines for people during outbreaks

67 (Gouglas et al. 2019; Bernasconi et al. 2020; Huneycutt et al. 2020). The first call for proposals  
68 from CEPI was on developing vaccines for Lassa virus (LASV), MERS coronavirus (MERS-  
69 CoV), and Nipah virus (NiV). Soon after, it added Rift Valley fever virus (RVFV) and  
70 chikungunya virus (CHIKV) to its portfolio. As of early 2021, CEPI was supporting development  
71 of a total of 19 different vaccine candidates for these five diseases, in addition to other efforts  
72 related to Ebola, COVID-19, and “disease X” (CEPI 2018).

73 In anticipation of vaccine candidates for these diseases progressing through safety and efficacy  
74 trials and towards implementation, there is a need to understand future potential vaccine  
75 demand (Røttingen et al. 2017). Even though these vaccines are not yet available for public  
76 health use, understanding demand at an early stage is important to inform fundraising and  
77 planning efforts in support of the manufacturing and distribution infrastructure that will be  
78 required for their implementation (Excler et al. 2021). Following the development of a new  
79 vaccine, manufacturing capacities are typically the first limiting factor for vaccine supply, which  
80 raises allocation and prioritization decisions to protect people at higher risk of infection and  
81 clinical disease (Medlock and Galvani 2009; Bubar et al. 2021). Appropriate planning of vaccine  
82 stockpiles to support vaccine demand is important to minimize the extent to which difficult  
83 decisions about vaccine prioritization must be made once a vaccine becomes available for use.  
84 At the same time, overestimating vaccine stockpile needs could result in doses expiring and  
85 resources that could have gone to other needs being wasted.

86 To improve capabilities to plan vaccine stockpiles for emerging zoonotic pathogens, we  
87 developed a modeling framework to quantify the vaccine stockpile size needed to meet demand  
88 for outbreak response and applied it to LASV, MERS-CoV, NiV, and RVFV (Figure 1). Each of  
89 these pathogens is zoonotic, with the majority of human cases believed to result from spillover  
90 transmission from non-human hosts accompanied by self-limiting, human-to-human  
91 transmission (Linthicum, Britch, and Anyamba 2016; Cauchemez et al. 2016; Siddle et al. 2018;  
92 Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et  
93 al. 2019). Our model is driven by geographically and seasonally realistic patterns of spillover for  
94 each pathogen, with each spillover event having the potential to spark an outbreak that we  
95 simulated stochastically with a branching process model. Outbreak response with reactive  
96 vaccination was triggered in our model whenever a threshold number of cases was exceeded  
97 within a certain space-time window. We quantified the number of vaccine regimens required  
98 (where the number of regimens equals the number of individuals vaccinated) under three  
99 different approaches to reactive vaccination: 1) population-wide within the same geographic  
100 area as the outbreak, 2) targeted on healthcare workers (HCWs) within that area, or 3) targeted  
101 on a ring of contacts around each index case. Using vaccines modeled after target product  
102 profiles for each pathogen (WHO 2017c, 2017b, 2017a, 2019), we also quantified the impact of  
103 reactive vaccination under a range of scenarios about deployment timing, coverage, per-  
104 exposure protection (PEP) from vaccination, and several epidemiological parameters.

105



107 **Figure 1. Overview of this study.** We considered four emerging zoonoses prioritized by the WHO R&D  
 108 Blueprint and CEPI. For each, we modeled spillover, human-to-human transmission, and reactive  
 109 vaccination. We quantified the vaccine stockpile necessary to meet demands of reactive vaccination  
 110 under three scenarios: vaccinating an entire population within the same geographic area as a detected  
 111 outbreak, vaccinating healthcare workers within that geographic area, or vaccinating contacts associated  
 112 with each spillover case. **Lassa fever** is caused by LASV, a virus that circulates in rodents in West Africa  
 113 and has resulted in thousands of cases and deaths in recent years (Mylne et al. 2015; Roberts 2018).  
 114 **Nipah** is caused by NiV, a virus that circulates in fruit bats that can be found throughout tropical and  
 115 subtropical Asia (Yob et al. 2001; Luby et al. 2009), but documented spillover to humans has been mainly  
 116 limited to India, Bangladesh, and Malaysia (Pulliam et al. 2012; Girish Kumar et al. 2019; Nikolay, Salje,  
 117 Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019). **MERS** is  
 118 caused by MERS-CoV, a coronavirus that probably originated in bats (Anthony et al. 2017), and is known  
 119 to circulate among domestic camel populations in the Middle East and parts of eastern and northern  
 120 Africa, resulting in spillover from camels to humans (Müller et al. 2015; Dudas et al. 2018; Hui et al.  
 121 2018). Human-to-human transmission has been reported in nosocomial settings for three of these  
 122 pathogens (Fisher-Hoch et al. 1995; Park et al. 2016; Nikolay, Salje, Hossain, Khan, Sazzad, Rahman,  
 123 Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019), although only MERS was reported in large  
 124 hospital outbreaks (Assiri, McGeer, et al. 2013; Park et al. 2016). The evidence for community  
 125 transmission of these viruses is more limited (Siddle et al. 2018; Hui et al. 2018; Nikolay, Salje, Hossain,  
 126 Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019). **Rift Valley fever** is  
 127 caused by RVFV, a mosquito-transmitted virus infecting ruminant livestock species in Africa, the Arabian  
 128 Peninsula, and the Indian Ocean islands (Pepin et al. 2010; Bron et al. 2021; Gerken et al. 2021). RVF  
 129 outbreaks have been associated with heavy rainfall in eastern and southern Africa (Anyamba et al. 2009,  
 130 2010), but transmission can also occur outside of these epizootic events (Linthicum, Britch, and Anyamba  
 131 2016). Humans can be infected via direct contact with infected animals or via mosquito bite, but are  
 132 believed to be dead-end hosts (Al-Hamdan et al. 2015).

133  
 134

## 135 **Methods**

136

### 137 *Epidemiological data*

138

139 For each of the pathogens, we collated epidemiological data through the end of 2020 from  
140 multiple sources, including WHO outbreak reports (e.g., (CSR n.d.)), ProMED reports  
141 (<https://promedmail.org>), country-level reports (<https://www.moh.gov.sa>, <https://ncdc.gov.ng>),  
142 and a literature search. A detailed overview of the source of epidemiological data for each  
143 pathogen can be found in the Supplementary Table S1.

144

### 145 *Spillover simulation*

146 Given extensive spatial heterogeneity of incidence, we collated epidemiological data at the first  
147 administrative level (adm1) in each country—e.g., province or state—within the study region for  
148 each pathogen. The primary epidemiological data used to inform spillover rates was the annual  
149 incidence of reported cases of each pathogen at the adm1 level (Table S1). Where possible,  
150 case data was categorized into cases of documented or suspected human-to-human  
151 transmission, documented or suspected spillover cases, and cases of unknown origin. The  
152 geographic coverage of our analysis for each pathogen was determined by the geographic  
153 distribution of spillover cases in the literature. All countries with at least one documented  
154 spillover case were included in our analysis. We excluded countries with imported cases but no  
155 spillover from a zoonotic source (e.g., South Korea for MERS-CoV).

156 Spillover rates were estimated using a generalized linear mixed model (GLMM) with a zero-  
157 inflated negative binomial distribution to capture overdispersion in the annual distribution of  
158 spillover cases within an adm1. Spillover cases were defined as documented spillover cases,  
159 suspected spillover cases, or cases of unknown origin; thereby excluding any cases of  
160 documented or suspected human-to-human transmission. Year, country, and adm1 were  
161 treated as random effects, with the adm1 variable nested within the country variable. Year was  
162 also included as a random effect for the zero-inflated portion of the model. Model fitting was  
163 conducted using the glmmTMB package in R (Brooks et al. 2017). This default model did not  
164 converge for NiV; therefore, for NiV we used the GLMM model without the random effect by  
165 year in the zero-inflated portion of the model to enable convergence. Then, for each pathogen,  
166 we simulated annual spillover cases for each year and adm1 by taking draws (1,000 replicates)  
167 from a zero-inflated negative binomial distribution using the estimated parameters from the  
168 appropriate GLMM fit. We randomly sampled 1,000 of these simulated spillovers from the last  
169 five years as inputs to the outbreak simulation model so that the simulated spillovers would  
170 reflect recent spillover rates.

171

172 To account for the seasonality of spillover, we fitted a beta distribution to the timing of spillover  
173 cases within a year (daily for MERS, weekly for Lassa fever, monthly for Nipah and RVF) and  
174 simulated the timing of each spillover case as a random draw from that distribution (Table 1). To  
175 account for spatial clustering of cases below the adm1 level, we associated each simulated  
176 case with a catchment area. We did so according to probabilities proportional to catchment area  
177 population. Catchment areas were defined by second administrative level (adm2) or hospitals

178 aggregated within 10 km for first administrative (adm1) areas that did not have an adm2 level.  
179 These catchment areas, therefore, represent areas where individuals would be expected to  
180 seek care and have their diagnosis reported, and the aggregation of hospitals within a 10km  
181 area assumes that individuals who seek treatment for the relatively severe symptoms of these  
182 diseases do so at larger hospitals. Hospital location data for sub-Saharan Africa used in the  
183 analysis of LASV was obtained from (Maina et al. 2019), and hospital location data outside of  
184 sub-Saharan Africa was obtained from <https://www.healthsites.io> (Saameli et al. 2018). The  
185 primary set of findings we reported are based on a set of 1,570 catchment areas for LASV, 767  
186 for MERS-CoV, 5,076 for NiV and 2,126 for RVFV, which differ because of the different  
187 geography of each pathogen. We examined the sensitivity of our results to the definition of a  
188 catchment area by rerunning the analyses with either adm1 catchment areas or all hospitals  
189 within an adm1 as distinct catchment areas. The results of these analyses are presented in the  
190 Supplement (SI Text).

191


### 192 *Outbreak simulation*

193

194 To simulate incidence attributable to human-to-human transmission, we considered each  
195 spillover case as a potential index case for an outbreak. A schematic overview of both the  
196 spillover and outbreak simulation models, including outbreak response, is provided in Figure 2.  
197 Human-to-human transmission was simulated stochastically using a branching process model.  
198 For each primary case, a certain number of secondary cases was drawn either from a Poisson  
199 distribution (for Lassa fever and RVF) with  $\lambda = R_0$ , or from a negative binomial distribution (for  
200 MERS and Nipah) with  $\mu = R_0$  and a dispersion parameter,  $k$ . A Poisson distribution was used  
201 for Lassa fever and RVF, because both have an estimated  $R_0 < 0.1$  and no available estimate of  
202 overdispersion. We used a negative binomial distribution for MERS and Nipah, because  
203 secondary cases for these diseases are known to be overdispersed, with a majority of human-  
204 to-human transmission arising from a small minority of primary cases (Cauchemez et al. 2016;  
205 Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, and  
206 Others 2019).

207





<sup>S</sup> Model inputs that were varied as part of our sensitivity analysis

209 **Figure 2. Schematic of the spillover simulation and outbreak simulation models.** The spillover  
 210 simulation model estimates the magnitude and timing (seasonality) of the spillover rate for each  
 211 catchment area from the historical distribution of reported spillovers in the catchment area. These  
 212 estimated spillover rates are input into our outbreak model for each catchment area (as identified by the  
 213 bolded model input), which used a branching process model to simulate human-to-human transmission.  
 214 An outbreak response was triggered within a catchment area if the number of reported cases exceeded a  
 215 predetermined number within a 28d time window (outbreak threshold size). Outbreak model inputs with a  
 216 superscript S were varied as part of our sensitivity analysis.

217  
 218 We estimated  $R_0$  and variability therein differently for each pathogen. For LASV, we estimated  
 219 an  $R_0$  for nosocomial transmission by fitting a simple branching process model to observed  
 220 outbreak sizes from (Lo Iacono et al. 2015) using the optimize function in R and assuming a  
 221 Poisson offspring distribution (Farrington, Kanaan, and Gay 2003). The resulting estimate of  $R_0$   
 222 for LASV was 0.063 (95% confidence interval [CI]: 0.05 - 0.08) (Table 1). For MERS-CoV, we  
 223 compiled estimates of  $R_0$  from multiple studies analyzing data from MERS outbreaks  
 224 (Cauchemez et al. 2014; Breban, Riou, and Fontanet 2013; Poletto et al. 2014; Chowell et al.  
 225 2014; Cauchemez et al. 2016; Kucharski and Althaus 2015) and described variability in those  
 226 estimates with a gamma distribution, which resulted in a median  $R_0$  of 0.583 (90% CI: 0.31 -  
 227 0.99). The dispersion parameter estimate,  $k=0.26$ , for MERS-CoV was obtained from (Kucharski  
 228 and Althaus 2015). For NiV, we estimated  $R_0$  and its variability from detailed epidemiological  
 229 investigations of Nipah outbreaks in Bangladesh that estimated person-to-person chains of NiV  
 230 transmission (Nikolay 2019). Using data from these studies on the number of secondary

231 infections per primary infection and the size of each transmission cluster, we obtained  
 232 maximum-likelihood estimates of  $R_0$  (0.33, 95% CI: 0.21 - 0.52) and  $k$  (0.048, 95% CI: 0.031 -  
 233 0.074), which were consistent with a branching process with a negative binomial offspring  
 234 distribution. For RVFV, we assumed  $R_0=0$ , and considered  $R_0=0.01$  for sensitivity analysis only,  
 235 as no human-to-human transmission has been definitively documented to date (Al-Hamdan et  
 236 al. 2015).

237 The timing of incubation and infectious periods were then simulated subsequently based on  
 238 gamma distributions of those periods that we estimated by fitting a model to reconcile variability  
 239 in previously published estimates (Table 1). As no human-to-human transmission is known for  
 240 RVFV, we assumed for the sensitivity analysis a fixed duration for the infectious period of 7  
 241 days that is consistent with the duration of detectable viremia after onset of symptoms (Bird et  
 242 al. 2009). For all pathogens, the infection date of secondary cases was simulated as a draw  
 243 from a uniform distribution over the infectious period of the primary case. Each secondary case  
 244 was assigned to the same catchment area as the associated index case. A detailed overview of  
 245 the source for each parameter of each pathogen can be found in the Supplementary Table S1.  
 246

247 **Table 1. Overview of parameter estimates.** Incubation period and infectious period are  
 248 defined in units of days, and parameters for seasonality refer to week of the year. Numbers in  
 249 parentheses for  $R_0$  represent the 95% confidence intervals.

| Parameter         | LASV               | MERS-CoV          | NiV                | RVFV           |
|-------------------|--------------------|-------------------|--------------------|----------------|
| Seasonality       |                    |                   |                    |                |
| - Peak (wk)       | 31.1               | 23.3              | 27.3               | 23.2           |
| - SD (wk)         | 6.2                | 13.6              | 6.4                | 12.7           |
| Incubation period |                    |                   |                    |                |
| - Mean (d)        | 12.05              | 5.56              | 9.87               | 2.88           |
| - SD (d)          | 3.62               | 0.77              | 0.84               | 1.95           |
| Infectious period |                    |                   |                    |                |
| - Mean (d)        | 11.31              | 13.5              | 6.49               | 7 <sup>1</sup> |
| - SD (d)          | 8.29               | 2.61              | 0.26               | -              |
| $R_0$             |                    |                   |                    |                |
| - Mean            | 0.063 (0.05, 0.08) | 0.58 (0.31, 0.99) | 0.325 (0.21, 0.52) | 0 (0.01)       |
| - Dispersion      | -                  | 1.42              | 0.048              | -              |

250 <sup>1</sup> Fixed value used for sensitivity analysis only.

251

### 252 *Vaccine campaign simulation*

253

254 Three different reactive vaccination strategies were evaluated: 1) vaccinating a portion of the  
 255 general population in a given catchment area; 2) specifically targeting the HCWs in that  
 256 catchment area; or 3) adopting a ring vaccination strategy where the local population  
 257 surrounding each index case are targeted for vaccination. These strategies were chosen as  
 258 they represent three of the most frequently deployed outbreak response strategies. For each  
 259 strategy, baseline vaccination campaign parameter values (and parameter ranges for the  
 260 sensitivity analysis) were based on vaccine target product profiles for each pathogen (WHO



261 2017c, 2017b, 2017a, 2019), or chosen in consultation with CEPI and subject-matter experts for  
262 each pathogen (Table 2).

263  
264 To estimate the impact of vaccination, we simulated each outbreak response relative to a  
265 counterfactual simulation in which there was no outbreak response. Vaccination impact was  
266 defined as the number of cases averted via vaccination and calculated by taking the difference  
267 between the number of cases in the vaccination and no-vaccination scenarios. In our baseline  
268 scenario, an outbreak response within a single catchment area was triggered once ten cases for  
269 Lassa fever and MERS or three cases for Nipah and RVF were detected within a four-week  
270 window (Table 2). These outbreak response thresholds were chosen through discussion with  
271 CEPI and pathogen experts, and do not necessarily match the different outbreak definitions  
272 currently used by WHO or individual countries. The vaccination start date was calculated by  
273 adding a delay to the outbreak response date. To simplify vaccine uptake in our model, we  
274 assumed that each target population was immunized on a single day. Multi-day vaccination  
275 campaigns would likely reduce the impact of outbreak response relative to our estimates, but  
276 this impact would be less severe than a comparable delay in protection following vaccination  
277 because at least a portion of the population would be protected at the beginning of the  
278 campaign. Therefore, our analysis of the sensitivity of vaccination impact to a delay in protection  
279 following vaccination could be considered an upper bound on the sensitivity to extending the  
280 vaccine administration period for a given round of vaccination. In the case of a 2-dose vaccine,  
281 an additional delay of 28 days was assumed between administration of the first and second  
282 doses.

283  
284 For the general population vaccination strategy, HCWs were treated as part of the general  
285 population and were vaccinated with the same probability as the general population. For the  
286 HCW vaccination strategy, non-HCWs were not vaccinated, except for a hybrid strategy tested  
287 as part of our sensitivity analysis, where 20% of the general population was vaccinated versus  
288 80% of HCWs (Table 2). For the ring vaccination strategy, we calculated the number of index  
289 cases that would arise after the reactive vaccination campaign had started and assumed that 90  
290 vaccine regimens would be needed to vaccinate a ring of individuals around each index case  
291 based on estimates from ring vaccination campaigns during recent Ebola and cholera outbreaks  
292 (Ali et al. 2016; Henao-Restrepo et al. 2017). For the ring vaccination strategy, we only  
293 estimated the number of vaccine regimens that would be required and did not attempt to  
294 estimate the impact of vaccination on cases averted, because our model was designed to  
295 simulate a single vaccine campaign and not the periodic deployment as required by a ring  
296 vaccination strategy.

297  
298 Once a vaccination campaign was completed and the delay between vaccination and protective  
299 immunity had elapsed, vaccination in the general population removed spillover cases with a  
300 probability equal to vaccination coverage in the general population multiplied by per-exposure  
301 protection (PEP). Vaccination of the general population also removed patient-to-HCW  
302 nosocomial cases with probability equal to vaccination coverage in HCWs multiplied by PEP.  
303 Vaccination of HCWs had no impact on spillover cases, but it removed nosocomial cases with  
304 probability equal to vaccination coverage in HCWs multiplied by PEP. PEP depended on

305 whether a sufficient amount of time since vaccination had elapsed and, in the event of a two-  
 306 dose vaccine, whether an individual had received one dose or two doses at the time of  
 307 exposure (Table 2). Cases downstream in a transmission chain from a case averted by  
 308 vaccination were also averted.

309  
 310 **Table 2. Overview of simulation scenarios.** Parameter values for the baseline reactive  
 311 vaccination scenario for each pathogen. Outbreak response threshold cases and threshold  
 312 window refer to the number of cases that need to occur within a certain time window to trigger  
 313 an outbreak response. Parameter values in parentheses are alternative values used as a part of  
 314 the sensitivity analysis.

| Parameter   | LASV, MERS-CoV   | NiV, RVFV    |
|---|------------------|--------------|
| Outbreak response                                 |                  |              |
| - Threshold cases                                 | 10 (5)           | 3 (1, 5)     |
| - Threshold window                                | 28d              | 28d          |
| - Delay   | 28d (7, 120)     | 28d (7, 120) |
| Vaccination                                       |                  |              |
| - Coverage HCW <sup>1</sup>                       |                  |              |
| - Coverage population                             | 70% (80, 50, 90) |              |
| - Delay between dose                              | 70% (20, 50, 90) |              |
| - Regimens per index case (ring vaccination only) | 28d              |              |
|   | 90               |              |
| Per-exposure protection (PEP)                     |                  |              |
| - Single dose                                     | 70% (50%, 90%)   |              |
| - Two dose 1st                                    | 35% (25%, 45%)   |              |
| - Two dose 2nd                                    | 70% (50%, 90%)   |              |
| - Delay   | 7d (14)          |              |

315 <sup>1</sup> Excluded for RVFV as no nosocomial transmission has been documented.

316  
 317 *Vaccine demand calculation*

318  
 319 To quantify the number of regimens required to meet the demands of a given outbreak  
 320 response strategy, we estimated the number of healthcare workers and overall population  
 321 associated with each catchment area where an outbreak occurred. The overall population per  
 322 catchment area was estimated based on WorldPop data from 2015 (Tatem 2017). For  
 323 healthcare workers, we took the national-level numbers of healthcare workers and distributed  
 324 them proportional to the population associated with each catchment area (Ref (WHO 2021)).

325  
 326 *Graphical user interface*

327  
 328 A generalized implementation of the model is provided as a graphical user interface (GUI) at  
 329 <http://eidvaccinedemand.crc.nd.edu>. In the generalized implementation, a few adjustments were  
 330 made to allow for more flexible application of the model and to make computing time more  
 331 acceptable for an interactive web tool. First, annual spillovers are drawn from a negative  
 332 binomial distribution and then distributed across the catchment areas with a multinomial  
 333 distribution proportional to the probability that spillovers occur in these catchment areas.

334 Second, the population in the catchment areas were defined by a negative binomial distribution  
335 so that specific geographies did not need to be reproduced. The default parameters for the GUI  
336 of each pathogen were obtained by fitting the corresponding distribution function to the  
337 estimated spillover and population data from this study. The source code for the GUI is provided  
338 at [https://github.com/lerch-a/CEPI\\_VaccineCampaignGUI](https://github.com/lerch-a/CEPI_VaccineCampaignGUI).

339

## 340 **Results**

341

### 342 *Spillover cases and human-to-human transmission*

343

344 The median annual number of spillover cases was 6 (95% prediction interval: 0-190) for Nipah,  
345 114 (95% PrI: 48-266) for MERS, 185 (95% PrI: 8-13,134) for RVF, and 417 (95% PrI: 142-  
346 1,837) for Lassa fever (Figure 3A). Simulated variability in the annual number of spillover cases  
347 matched the cumulative distribution of observed spillover cases for each pathogen (SI Figures  
348 S1B-S4B). Spillover rates for each pathogen varied both seasonally (SI Figures S1A-S4A) and  
349 geographically (Figure 4A). Spillover cases of Lassa fever were concentrated in Sierra Leone,  
350 Liberia, and Nigeria, although a few spillover cases occurred in other western African countries.  
351 Spillover of RVF to humans was widespread in South Africa, Madagascar, eastern Africa and  
352 the Arabian Peninsula, with frequent spillover cases occurring in several western and northern  
353 Africa countries as well. The majority of MERS spillover cases occurred in Saudi Arabia, and the  
354 majority of Nipah spillover cases occurred in Bangladesh, with additional spillover events in  
355 India and Malaysia.

356

357 The number of cases arising from human-to-human transmission depended on both the  
358 spillover rate and  $R_0$  (Figure 3A). Under our default parameter assumptions, there was no  
359 human-to-human RVFV transmission, but in the absence of vaccination the median annual  
360 number of human-to-human cases following spillover was 2 (95% PrI: 0-82) for Nipah, 29 (95%  
361 PrI: 11-143) for Lassa fever, and 161 (95% PrI: 46-407) for MERS (see Figure 5 for an example  
362 of the transmission chains for one catchment area).


363

### 364 *Estimates of vaccine demand*

365


366 In our analysis, a median of 0 (95% PrI: 0-8) Nipah reactive vaccination campaigns were  
367 triggered annually, compared to 4 (95% PrI: 0-11) MERS campaigns, 5 (95% PrI: 0-20) RVF  
368 campaigns, and 0 (95% PrI: 0-20) Lassa fever campaigns (Figure 3B). The locations of reactive  
369 vaccination campaigns broadly followed the geographic distribution of spillovers for each  
370 pathogen, although Lassa fever spillovers in Guinea, Benin, Togo, and western Nigeria were  
371 rarely reported frequently enough to trigger a response in our simulations (Figure 4B). The  
372 number of reactive vaccination campaigns that were triggered, and the timing of those  
373 campaigns, was strongly influenced by the seasonal pattern of pathogen spillover (SI Figures  
374 S1-S4).

375




377 **Figure 3. Simulated annual cases and reactive vaccination impacts.** (A) Annual number of spillover,  
 378 human-to-human (H2H), and total cases for each pathogen across the entire study region (in the absence  
 379 of vaccination). (B) Violin plot (including box plot representing the median, IQR, and 95% CI) of the  
 380 annual number of vaccine campaigns triggered due to the outbreak threshold being exceeded across  
 381 1,000 simulations for each pathogen. (C) Number of vaccine regimens required per year for reactive  
 382 vaccination under our baseline scenario under three alternative assumptions about the target of  
 383 vaccination campaigns. (D) Violin plot (including box plot representing the median, IQR, and 95% CI) of  
 384 annual number of cases averted by reactive vaccination campaigns across 1,000 simulations for each  
 385 pathogen. All y-axes are log<sub>10</sub> scaled.

386  
 387  
 388



391 **Figure 4. Geographic distribution of predicted spillover cases and reactive vaccination**  
392 **campaigns.** (A) Geographic distribution at the 2<sup>nd</sup> administrative level (adm2) of the expected annual  
393 number of spillover cases for each pathogen. (B) The annual probability that a campaign will be triggered  
394 in each adm2 catchment area based on 1,000 simulations.

395  
396



397  
398 **Figure 5. Timing of spillover and nosocomial cases in a single realization of one catchment area**  
399 **from the MERS-CoV outbreak model.** (Bottom) Individual cases are visualized as thick horizontal lines,  
400 with observed cases in yellow/orange and averted cases in gray (yellow and light gray indicate incubation  
401 time, orange and dark gray indicate infectious time). Unrelated transmission trees are separated by thin  
402 horizontal gray lines. The dashed vertical line indicates the date the outbreak threshold was reached.  
403 Triangles indicate vaccination date and diamonds indicate protection date. (Top) Number of observed  
404 (orange) and averted (gray) cases per week.  
405

406 For all four pathogens, there was a wide range in the number of vaccine regimens required in a  
407 typical year due to the dependence of vaccine demand on the spatiotemporal clustering of  
408 spillover cases required to trigger an outbreak response. The largest annual vaccine demand



409 was for RVFV, with a median of 1,191,741 (95% PrI: 0-8,480,275) vaccine regimens required to  
410 target the general population under our baseline outbreak response scenario (Figure 3C). The  
411 median number of vaccine regimens for MERS-CoV was 870,045 (95% PrI: 0-2,843,407). The  
412 median number of vaccine regimens needed for NiV and LASV was zero, implying that an  
413 outbreak response was triggered less than 50% of the time. However, the mean number of  
414 vaccine regimens was 673,167 (95% PrI: 0-3,629,052) for LASV and 1,450,177 (95% PrI: 0-  
415 12,240,814) for NiV (Figure 3C). The number of vaccine regimens required to conduct a ring  
416 vaccination strategy or to cover healthcare workers as a part of an outbreak response was  
417 typically several orders of magnitude (between 1/25 and 1/700) lower than the number required  
418 to cover the general population (Figure 3C). The median number of MERS-CoV vaccine  
419 regimens required to cover healthcare workers was 6,786 (95% PrI: 0-22,086). A median of  
420 1,540 (95% PrI: 0-62,320) vaccine regimens were needed among healthcare/veterinary workers  
421 for RVFV outbreak response, 0 (mean: 1,144; 95% PrI: 0-6,485) were required for LASV, and 0  
422 (mean: 2,330; 95% PrI: 0-15,833) for NiV. The median number of vaccine regimens required for  
423 ring vaccination was 4,860 (95% PrI: 0-21,429) for MERS-CoV, 12,150 (95% PrI: 0-1,175,758)  
424 for RVFV, 0 (mean: 13,774; 95% PrI: 0-108,056) for LASV, and 0 (mean: 2,605; 95% PrI: 0-  
425 21,641) for NiV.

426

#### 427 *Impact of outbreak response*

428

429 The estimated impact of reactive vaccination as an outbreak response tool was generally low for  
430 all four pathogens. Vaccinating 70% of the general population in response to an outbreak with a  
431 single-dose vaccine prevented an annual median of 43 (95% PrI: 0-5,853) RVF cases, 6 (95%  
432 PrI: 0-83) MERS cases, 0 (95% PrI: 0-90) Nipah cases, and 0 (95% PrI: 0-357) cases of Lassa  
433 fever (Figure 3D). These vaccine impacts correspond to 0.69 (95% PrI: 0-2.92) cases averted  
434 per 100,000 vaccine regimens administered for MERS, 3.61 (95% PrI: 0-69.02) for RVF, 0 (95%  
435 PrI: 0-9.84) for Lassa fever, and 0 (95% PrI: 0-0.74) for Nipah. Vaccinating only healthcare  
436 workers typically had a smaller total impact than vaccinating the general population at the same  
437 coverage level, because there was no protection against spillover in the general population, but  
438 a larger per-regimen impact due to the lower number of regimens required. Vaccinating 70% of  
439 HCWs prevented an annual median of 4 (95% PrI: 0-77) MERS cases, corresponding to 58.9  
440 (95% PrI: 0-348.6) cases averted per 100,000 vaccine regimens in HCWs. Vaccinating HCWs  
441 averted 0 (95% PrI: 0-46) Lassa fever cases and 0 (95% PrI: 0-48) Nipah cases, corresponding  
442 to 0 (95% PrI: 0-710.4) and (95% PrI: 0-303.5) cases averted per 100,000 HCW vaccine  
443 regimens respectively (we did not explore vaccinating HCWs against RVFV due to the lack of  
444 any documented nosocomial transmission).

445

#### 446 *Sensitivity analysis*

447

448 The number of total cases increased with higher  $R_0$  values for each pathogen, with the largest  
449 sensitivity observed for MERS-CoV, because its higher value of  $R_0$  was close to one (Figure  
450 S16). There was also a large increase in the number of vaccine regimens required to vaccinate  
451 either the general population or HCWs for MERS-CoV at the higher  $R_0$  value, but the impact of  
452  $R_0$  on the required number of vaccine regimens was minimal for the other pathogens (Figures

453 S17-S18). As a result, there were minimal differences in the impact of vaccination under higher  
454 or lower  $R_0$  values for LASV, NiV, or RVFV (Figures S19-S22). Vaccination averted both a  
455 greater magnitude and a higher fraction of MERS cases as  $R_0$  increased (Figures S19-S20). In  
456 addition, the number of MERS cases averted per vaccine regimen administered to the general  
457 population or to HCWs also increased as  $R_0$  increased (Figures S21-S22).


458  
459 Lowering the outbreak threshold (from 10 to 5 cases within a 28 day window for MERS-CoV and  
460 LASV, and from 3 to 1 cases for NiV and RVFV) increased both the number of vaccine  
461 regimens needed for outbreak response and the number of cases averted. With the lower  
462 outbreak threshold, the projected demand for MERS-CoV vaccine regimens was 2,351,059  
463 (95% PrI: 492,028-5,872,847), a 170% increase, while the median number of cases averted  
464 was 19 (95% PrI: 0-162), a 217% increase compared to the baseline. The required number of  
465 vaccine regimens for RVFV increased to 4,793,351 (95% PrI: 659,297-14,157,197), a 302%  
466 increase, while the median number of RVF cases averted was 66 (95% PrI: 0-6,066), a 53%  
467 increase. The median number of vaccine regimens for LASV increased from 0 to 756,273 (95%  
468 PrI: 0-6,644,995), and the median number of Lassa fever cases averted increased from 0 to 15  
469 (95% PrI: 0-534). The median number of vaccine regimens for NiV increased from 0 to  
470 3,501,587 (95% PrI: 0-54,814,275), but the median number of cases averted remained 0 (95%  
471 PrI: 0-119). When the outbreak threshold was increased to 5 cases for RVF, the required  
472 number of vaccine regimens decreased by 50% to 594,894 (95% PrI: 0-7,493,183). The number  
473 of RVF cases averted via vaccination decreased to 26 (95% PrI: 0-5,735), which was 41% fewer  
474 cases averted compared with an outbreak threshold of 3 cases.

475  
476 Decreasing the time delay between the outbreak threshold being reached and the start of the  
477 vaccination campaign tended to increase the number of cases averted, while increasing the  
478 delay reduced the number of cases averted (Figure 6). For MERS-CoV, reducing the time delay  
479 from 28 to 7 days increased the median number of cases averted from 6 (95% PrI: 0-83) to 14  
480 (95% PrI: 0-112), while increasing the delay to 120 days reduced the number of cases averted  
481 to 0 (95% PrI: 0-38).

482  
483 Increasing or decreasing the percentage of the population that was targeted during reactive  
484 vaccination campaigns also led to corresponding increases or decreases in the number of  
485 cases averted (Figure 6). For example, if only 50%, rather than 70%, of the population was  
486 vaccinated for MERS-CoV, the median number of cases averted declined from 6 (95% PrI: 0-  
487 83) to 4 (95% PrI: 0-72). In contrast, if vaccination coverage was increased to 90%, then 7 (95%  
488 PrI: 0-93) MERS cases were averted. The number of MERS cases averted per 100,000 vaccine  
489 regimens administered decreased from 0.69 (95% PrI: 0-2.92) at 70% coverage, to 0.64 (95%  
490 PrI: 0-3.55) at 50% coverage, and 0.63 (95% PrI: 0-2.54) at 90% coverage. The sensitivity of  
491 the impact of outbreak response to other campaign parameters considered in our model,  
492 including per-exposure protection, time to protection following vaccination, vaccination coverage  
493 levels in HCWs, and one-dose vs. two-dose vaccines are provided in Figure 6. The sensitivity  
494 analyses for the other pathogens (NiV, LASV, and RVFV) and for different catchment levels are  
495 provided in the Supplement (SI Text). In general, the number of cases averted were highest  
496 when the spatial scale for vaccine response (catchment area) was the first administrative level,

497 but the per-regimen vaccination impact was higher for the smaller catchment areas (second  
 498 administrative level or hospital-based catchment areas), because fewer vaccine regimens were  
 499 required per campaign in those areas (Figures S33-S34).

500  
 501



503 **Figure 6. Vaccine impact sensitivity analysis for MERS-CoV.** Sensitivity of vaccination  
504 impact for MERS-CoV to variation in different campaign parameters expressed as (A) fraction of  
505 cases averted, (B) cases averted per 100,000 vaccinated in the general population, and (C)  
506 cases averted per 1,000 health care workers (HCWs) vaccinated.

507

## 508 **Discussion**

509

### 510 *Model performance*

511

512 Our spillover simulation model estimates closely matched the average annual reported number  
513 of spillover cases for each pathogen, as well as the observed interannual variability in the  
514 number of spillover cases that have occurred in the past few decades. The simulation results  
515 also captured the geographic distribution and seasonality of spillover cases for each pathogen.  
516 The magnitude, spatial distribution, and timing of spillover rates are the main determinants of  
517 how frequently an outbreak response threshold will be triggered and therefore the size of the  
518 vaccine stockpile needed for outbreak response. Although these patterns could shift to some  
519 degree in the future, our model represents what we know about them presently. In addition to  
520 influencing stockpile size, these three factors (the magnitude, spatial distribution, and timing of  
521 spillover rates) are also relevant for logistical considerations such as the geographic location(s)  
522 of the stockpile and the necessary stockpile replenishment rate (Yen et al. 2015).

523

### 524 *Stockpile estimates*

525

526 The estimated number of vaccine regimens needed to reach vaccination coverage targets in the  
527 general population varied considerably across the four pathogens examined. For both LASV  
528 and NiV, the median was zero, indicating that reactive vaccination campaigns would not be  
529 triggered more than 50% of the time. In contrast, the median numbers of vaccine regimens  
530 needed for MERS-CoV and RVFV were 870,000 and 1,190,000, respectively. However, the  
531 95% prediction intervals for all four pathogens were wide due to spatial and temporal  
532 heterogeneity in spillover rates and overdispersion in outbreak sizes resulting from human-to-  
533 human transmission. For all four pathogens, the vaccine regimens needed to target HCWs were  
534 several orders of magnitude lower than needed to target the general population.

535

536 These results indicate that the size of the vaccine stockpile needed to meet annual reactive  
537 vaccination demands will depend on the pathogen's epidemiology, the vaccine coverage  
538 strategy, and the specific demands of a sustainable manufacturing strategy. In addition to the  
539 median or mean annual vaccine demand, our estimates also provide an estimate of the inter-  
540 annual variability in vaccine demand and the potential magnitude of vaccine demand in low-  
541 frequency, but high-demand years. For example, the 75th or 90th percentile of our estimates  
542 correspond to the level of demand experienced once every four or ten years, on average. The  
543 desired size of a vaccine stockpile will likely depend not only on the average annual vaccine  
544 demand, but also on the stockpile capacity needed to adequately handle the unpredictability in  
545 the timing, frequency, geography, and magnitude of outbreaks. These questions will depend on  
546 sustainable vaccine manufacturing capacity, the geographic distribution of both this

547 manufacturing capacity and the stockpile, and vaccine shelf life. A graphical user interface is  
548 available at <http://eidvaccinedemand.crc.nd.edu> to facilitate interactive exploration of these  
549 dependencies.

550  
551 Our vaccine demand estimates indicate that the biggest determinant of the size of the reactive  
552 vaccine stockpile needs was the vaccination strategy: targeting the general population, only  
553 HCWs, or ring vaccination. For pathogens that primarily cause nosocomial outbreaks (e.g.,  
554 LASV), vaccinating HCWs can protect high-risk individuals. In our analysis, this strategy had a  
555 larger impact in terms of cases averted per vaccine regimen than vaccinating the general  
556 population. The impact of vaccinating HCWs will be highest when spillovers are highly spatially  
557 clustered because vaccination campaigns are more likely to be triggered in high-spillover  
558 catchment areas, thereby protecting HCWs against nosocomial transmission in areas where  
559 vaccination has already occurred earlier in the transmission season but where the spillover risk  
560 may remain high. A ring vaccination strategy would also require significantly fewer regimens  
561 than a general vaccination strategy. We estimated that the vaccine demand under a ring  
562 vaccination strategy would be similar to the demand under a HCW-vaccination strategy for  
563 LASV, NiV, and MERS-CoV, and moderately higher than the HCW-vaccination strategy for  
564 RVFV. Another strategy to reduce the number of vaccine regimens needed per reactive  
565 campaign that we did not consider in our analysis would be to target high-risk sub-populations  
566 instead of the whole population of a catchment area. In the case of RVFV, this would be animal  
567 workers like butchers, veterinarians, and farmers who are at highest risk of infection (Wilson et  
568 al. 1994; Nyakarahuka et al. 2018; Msimang et al. 2019). For MERS-CoV, camel workers have  
569 a higher risk of infection than the general population (Dudas et al. 2018). For LASV, rural  
570 populations within a catchment area are assumed to have a higher risk than urban populations  
571 (but see Chika-Igwenyi et al. 2021, where >50% of patients in one outbreak were urban  
572 residents). For NiV, rural populations and people drinking raw date palm sap could be targeted  
573 for vaccination (Rahman et al. 2012; Islam et al. 2016).

574  
575 In addition to providing an estimate of vaccine stockpile size, our modeling approach also  
576 provides an estimate of where the stockpile will most frequently need to be deployed. An  
577 understanding of the geographical distribution of vaccine demand is critical for sustainable  
578 manufacturing and timely response to outbreaks (Grais et al. 2008; Azman and Lessler 2015;  
579 Wells et al. 2019). Knowledge of vaccine needs by geographic area is essential so that the  
580 stockpile(s) can be strategically positioned for rapid deployment following the triggering of an  
581 outbreak response. Vaccine demand in a given area will be a function of the probability of an  
582 outbreak response being triggered and the size of the target population. Because we used a  
583 sliding time window for the outbreak threshold, the probability of a reactive vaccination  
584 campaign being triggered will also depend on the seasonality of spillover. Spillover cases that  
585 are highly seasonal will be more likely to trigger a response than spillovers that occur  
586 sporadically throughout the year. Highly seasonal spillover rates also increase the importance of  
587 rapid deployment of reactive vaccination campaigns, because the shorter duration of the  
588 transmission season increases the likelihood that any delays would cause campaigns to occur  
589 only after seasonal spillover transmission has declined.

590



591 The size of the outbreak-response catchment areas (our baseline catchment area at the 2nd  
592 administrative level vs. 1st administrative units or individual hospitals within each 1st  
593 administrative unit) also had a large impact on the frequency and timing of outbreak response.  
594 First-level administrative catchment areas triggered more outbreak responses and also have  
595 larger population sizes, and would therefore require a larger vaccine stockpile. However, this  
596 result assumes that the outbreak threshold (number of cases needed to trigger a reactive  
597 vaccination campaign) is the same regardless of the size of the catchment area. Adjusting the  
598 threshold size based on the geographic extent or population size of the catchment areas would  
599 alter the stockpile requirements and could be one approach to aligning expected stockpile  
600 demands with manufacturing capacity. The expected number of regimens needed for adm1  
601 catchment areas might also be an overestimate if only certain regions in an adm1 are at risk.  
602 Therefore, another approach that could balance the advantage of expanded adm1 catchment  
603 surveillance areas against the larger stockpile requirements would be to monitor spillover cases  
604 at the adm1 level, but limit reactive vaccination to the adm2 regions within the adm1 catchment  
605 area where spillover cases were observed.

606

### 607 *Vaccination impact*

608

609 Our results indicate that reactive vaccination strategies for preventing the transmission of  
610 zoonotic pathogens with  $R_0 < 1$  tend to have limited impacts. For each of the four pathogens we  
611 considered, reactive vaccination of the general population averted fewer than 100 cases per  
612 year on average and required more than 10,000 vaccine regimens per case averted. The  
613 largest impact (as measured by total cases averted or fraction of cases averted) was achieved  
614 for RVFV, which was the only pathogen where  $>5\%$  of total cases were averted via reactive  
615 vaccination under our default assumptions. On a cases-averted per regimen basis, vaccinating  
616 HCWs was more effective than vaccinating the general population for each of the pathogens  
617 with at least some human-to-human transmission in nosocomial settings (LASV, MERS-CoV,  
618 and NiV), suggesting that targeting this group may be a viable strategy for reducing the spread  
619 of zoonotic pathogens that are capable of nosocomial transmission.

620

621 Under our baseline reactive vaccination scenario, vaccination averted a higher proportion of  
622 RVF cases than cases of the other three diseases, even though we assumed that there was no  
623 human-to-human RVFV transmission. The higher impact of reactive vaccination for RVFV was  
624 the result of two factors. First, our default threshold to trigger an RVFV vaccination campaign  
625 was three cases (compared to 10 cases within a 28-day window for LASV or MERS-CoV),  
626 which led to more RVFV campaigns being triggered than for the other diseases. Second, RVFV  
627 spillovers are highly clustered in space and time, so additional spillover cases were often  
628 concentrated in catchment areas where previous spillovers during the transmission season had  
629 already triggered a reactive vaccination campaign. Although the lower threshold led to more  
630 vaccine regimens being required for RVFV than for the other pathogens, the per regimen impact  
631 of reactive vaccination was still highest for RVFV. These results highlight the importance of  
632 understanding the underlying epidemiology of zoonotic pathogens when assessing the  
633 feasibility of a reactive vaccination strategy. The spatial and temporal heterogeneity in spillover  
634 patterns will be a primary factor determining the potential impact of reactive vaccination for



635 pathogens where cases primarily occur via zoonotic spillover rather than human-to-human  
636 transmission. With a sensitive case threshold for triggering a vaccination campaign, and a  
637 relatively quick response time (28 days), our results indicate that ~25% of RVF cases could be  
638 averted. However, if the response time is slower (120 days), fewer than 5% of RVF cases would  
639 be averted via reactive vaccination. This highlights the importance of rapid response and  
640 vaccine deployment to the success of reactive campaigns when spillover is seasonal.

641  
642 After RVFV, the impact of vaccination was modestly higher for the pathogen (MERS-CoV) with  
643 the highest  $R_0$  (baseline  $R_0=0.58$ ), indicating that rapid deployment of a reactive vaccination  
644 campaign can avert a fraction of cases for pathogens capable of at least some sustained  
645 human-to-human transmission. However, even for MERS-CoV, fewer than 10% of annual cases  
646 were averted by reactive vaccination, even under our most optimistic scenario with a minimal  
647 delay. This was partly because a significant fraction of cases were spillover cases in geographic  
648 areas where no vaccination campaign was triggered, and partially because reactive vaccination  
649 often did not occur rapidly enough to avert a significant proportion of cases resulting from  
650 secondary human-to-human transmission. The one scenario where reactive vaccination had a  
651 large impact on MERS-CoV transmission was with a higher  $R_0$  value of 0.99. In this case, 84.0%  
652 (95% PrI: 10.7-97.5%) of MERS cases could be averted under our baseline reactive vaccination  
653 scenario, compared to only 2.1% (95% PrI: 0-18.2%) of cases averted with the default  $R_0=0.58$ .  
654 This result highlights the increased potential impact of a reactive vaccination strategy as  $R_0$   
655 approaches or exceeds one and self-sustaining human-to-human transmission chains that lead  
656 to larger outbreaks become more likely.

657  
658 *Reactive vs. prophylactic vaccination*

659  
660 Delays between the triggering of the outbreak threshold and vaccine administration limit the  
661 impact of reactive vaccination. In most simulated outbreaks, the outbreak died out before the  
662 vaccination was administered due to the low  $R_0$ . In light of this, prophylactic immunization of  
663 HCWs or people at high risk could have a larger impact than reactive vaccination. However, a  
664 potentially important aspect that was not considered in our study was the impact that reactive  
665 vaccination campaigns in one year had for protection in subsequent year(s). Depending on the  
666 duration of vaccine-derived immunity, the number of cases averted in subsequent years could  
667 be substantial, particularly if the geographic clustering of spillovers is fairly consistent from year  
668 to year. For example, in the past few years, some catchment areas in Nigeria have experienced  
669 outbreaks of Lassa fever multiple years in a row (Siddle et al. 2018; Roberts 2018). As an  
670 extension of our work, the number of averted cases in the years following a reactive vaccination  
671 campaign could be estimated based on the spillover rate, the probability of an outbreak, and the  
672 durability of vaccine-derived immunity.

673  
674 *Limitations*

675  
676 We have attempted to estimate vaccine stockpile needs and identify the most important  
677 determinants of success for reactive vaccination of zoonotic emerging pathogens by modeling  
678 several vaccination strategies and exploring the sensitivity of our results to different aspects of

679 pathogen natural history and vaccine deployment. However, there are some limitations to our  
680 approach that could affect these estimates. We briefly mention the main limitations here and  
681 include an expanded discussion of these limitations in the SI Text.

682  
683 First, there is a relatively poor understanding of the epidemiology of most emerging zoonotic  
684 pathogens, and data that could be used to try and elucidate the most important aspects of their  
685 epidemiology is limited (Grange et al. 2021). In this study, we collated epidemiological data and  
686 parameter estimates from a variety of published sources and also consulted pathogen-specific  
687 experts, but, inevitably, our approach was limited by current knowledge. Second, because the  
688 modeling framework is intended to be applicable for a range of emerging zoonotic pathogens, it  
689 cannot incorporate all of the specific epidemiological details that might affect vaccine demand or  
690 impact for a particular pathogen. Our focus was on the key aspects of epidemiology and  
691 outbreak response that influence sustainable manufacturing needs, vaccine stockpile  
692 requirements, and the impact of outbreak response. Third, we only considered reported cases  
693 when estimating pathogen spillover rates, because undiagnosed or unreported infections would  
694 not trigger an outbreak response, which could bias the geographic distribution of vaccine  
695 demand away from areas with limited disease surveillance systems. This decision was made to  
696 ensure that our framework could be implemented with existing data only, and therefore could be  
697 applied to other pathogens in a straightforward manner.

698  
699 Fourth, because the extent of community transmission for each of the study pathogens is poorly  
700 understood, we assumed that human-to-human transmission was limited to nosocomial  
701 settings, which could result in an underestimate of vaccine demand. However, our modeling  
702 framework could be used to explicitly represent community transmission dynamics, and for  
703 pathogens with  $R_0 \ll 1$ , as was largely the case in this study, the limited size of the modeled  
704 transmission chains would be similar in either a community or hospital setting since we did not  
705 restrict the potential number of contacts per index case. Fifth, we also assumed that all  
706 nosocomial transmission was from patients to HCWs or between HCWs, and that there was no  
707 patient-to-patient or HCW-to-patient transmission. Therefore, our estimates of the impact of  
708 vaccinating HCWs represents an upper-bound on the effectiveness of this strategy, as  
709 instances of patient-to-patient transmission would not be prevented via this strategy. Sixth,  
710 another simplifying assumption of our model is that cases in one catchment area do not lead to  
711 transmission or an outbreak outside of that catchment area. However, our model already  
712 implicitly incorporates the possibility of spread between catchment areas, and although our  
713 model does not predict spillover cases occurring outside of each pathogen's currently  
714 documented geographic distribution, the reactive vaccination strategies we examined should  
715 also be applicable for responding to imported cases and their associated outbreaks. Finally, we  
716 did not consider any targeted vaccination strategies beyond ring vaccination or targeting  
717 healthcare workers to limit nosocomial outbreaks.

718  
719 *Conclusion*

720  
721 To inform the development of sustainable vaccine manufacturing processes for emerging  
722 pathogens, we developed a modeling framework to estimate the necessary reactive vaccine

723 stockpile size for emerging zoonotic pathogens. Our framework provides a flexible methodology  
724 for estimating vaccine stockpile needs for outbreak response, and for exploring the impact of  
725 epidemiology and vaccination strategies on outcomes that have important logistical implications  
726 for sustainable vaccine manufacturing, such as the geographic distribution of demand or the  
727 required stockpile replenishment rate. However, our model showed that the impact of reactive  
728 vaccination for the four pathogens that we explored was minimal, preventing fewer than 10% of  
729 human cases under most scenarios with their current epidemiology. However, all these  
730 pathogens are closely monitored for their outbreak potential, and control measures are needed.  
731 Targeting populations at higher risk of infection, such as HCWs, had a higher per-regimen  
732 impact than population-wide vaccination in outbreak control situations. Our results highlight the  
733 need for a more thorough epidemiological understanding of these, and other, emerging zoonotic  
734 pathogens. Improved pathogen surveillance and case detection are also essential for improving  
735 the model and our estimates of vaccine demand. Further work exploring additional scenarios,  
736 such as the possibility of targeting certain high-risk populations or the potential uses of vaccines  
737 for outbreak prevention rather than just outbreak response, is also needed to improve the  
738 potential impacts of vaccination.

739

#### 740 **Acknowledgements**

741

742 We thank Jim Robinson of CEPI and several members of the CEPI Scientific Advisory  
743 committee for helping formulate the reactive vaccination strategies examined in this manuscript  
744 and for providing feedback on our modeling framework. We thank John Edmunds (LASV),  
745 Robert Sumaye (RVFV), Bart Haagmans (MERS-CoV), Emily Gurley (NiV), and Steve Luby  
746 (NiV) for serving as pathogen-specific experts and providing assistance with identifying key  
747 epidemiological features and data gaps for their respective pathogens. We thank Nico Vandaele  
748 for feedback on how epidemiological modeling can help inform the planning and development of  
749 sustainable vaccine manufacturing. We thank Shweta Bansal and Romain Garnier for  
750 discussions regarding the modeling of emerging infectious disease outbreaks and vaccination.

751

#### 752 **Funding**

753

754 The following authors were supported by a contract from CEPI to the University of Notre Dame:  
755 AL, QAtB, QMT, JHH, ASS, ME, CH, KK, KS, MW, TAP, SMM.

756 **Supplementary Information**

757

758 **Table S1. Overview of data references.**

759 **Figure S1. Spillover and reactive vaccination patterns for Lassa fever virus (LASV).**

760 **Figure S2. Spillover and reactive vaccination patterns for Middle Eastern respiratory**  
761 **virus (MERS-CoV).**

762 **Figure S3. Spillover and reactive vaccination patterns for Nipah virus (NiV).**

763 **Figure S4. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV).**

764 **SI Text. Sensitivity analysis.**

765 **Figures S5-S34 in SI Text.**

766

767

768

769 **References**

- 770
- 771
- 772 Ahmad, Khabir. 2000. "More Deaths from Rift Valley Fever in Saudi Arabia and Yemen." *The*  
773 *Lancet* 356 (9239): 1422.
- 774 Ajayi, Nnennaya A. 2013. "Containing a Lassa Fever Epidemic in a Resource-Limited Setting:  
775 Outbreak Description and Lessons Learned from Abakaliki, Nigeria (January–March  
776 2012)." *International Journal of Infectious Diseases: IJID: Official Publication of the*  
777 *International Society for Infectious Diseases* 17 (11): e1011–16.
- 778 Al-Hamdan, Nasser A., Anil A. Panackal, Tami H. Al Bassam, Abdullah Alrabea, Mohammed Al  
779 Hazmi, Yagoub Al Mazroa, Mohammed Al Jefri, Ali S. Khan, and Thomas G. Ksiazek.  
780 2015. "The Risk of Nosocomial Transmission of Rift Valley Fever." *PLoS Neglected*  
781 *Tropical Diseases* 9 (12): e0004314.
- 782 Ali, Mohammad, Amanda K. Debes, Francisco J. Luquero, Deok Ryun Kim, Je Yeon Park,  
783 Laura Digilio, Byomkesh Manna, et al. 2016. "Potential for Controlling Cholera Using a  
784 Ring Vaccination Strategy: Re-Analysis of Data from a Cluster-Randomized Clinical  
785 Trial." *PLoS Medicine* 13 (9): e1002120.
- 786 Andersen, Kristian G., Andrew Rambaut, W. Ian Lipkin, Edward C. Holmes, and Robert F.  
787 Garry. 2020. "The Proximal Origin of SARS-CoV-2." *Nature Medicine* 26 (4): 450–52.
- 788 Anthony, S. J., K. Gilardi, V. D. Menachery, T. Goldstein, B. Ssebide, R. Mbabazi, I. Navarrete-  
789 Macias, et al. 2017. "Further Evidence for Bats as the Evolutionary Source of Middle  
790 East Respiratory Syndrome Coronavirus." *MBio* 8 (2).  
791 <https://doi.org/10.1128/mBio.00373-17>.
- 792 Antia, Rustom, Roland R. Regoes, Jacob C. Koella, and Carl T. Bergstrom. 2003. "The Role of  
793 Evolution in the Emergence of Infectious Diseases." *Nature* 426 (6967): 658–61.
- 794 Anyamba, Assaf, Jean-Paul Chretien, Jennifer Small, Compton J. Tucker, Pierre B. Formenty,  
795 Jason H. Richardson, Seth C. Britch, David C. Schnabel, Ralph L. Erickson, and  
796 Kenneth J. Linthicum. 2009. "Prediction of a Rift Valley Fever Outbreak." *Proceedings of*  
797 *the National Academy of Sciences of the United States of America* 106 (3): 955–59.
- 798 Anyamba, Assaf, Kenneth J. Linthicum, Jennifer Small, Seth C. Britch, Edwin Pak, Stephane de  
799 La Rocque, Pierre Formenty, et al. 2010. "Prediction, Assessment of the Rift Valley  
800 Fever Activity in East and Southern Africa 2006–2008 and Possible Vector Control  
801 Strategies." *The American Journal of Tropical Medicine and Hygiene* 83 (2\_Suppl): 43–  
802 51.
- 803 Archer, B. N., J. Thomas, J. Weyer, A. Cengimbo, D. E. Landoh, C. Jacobs, S. Ntuli, et al. 2013.  
804 "Epidemiologic Investigations into Outbreaks of Rift Valley Fever in Humans, South  
805 Africa, 2008-2011." *Emerging Infectious Diseases* 19 (12).  
806 <https://doi.org/10.3201/eid1912.121527>.
- 807 Arunkumar, Govindakarnavar, Radhakrishnan Chandni, Devendra T. Mourya, Sujeet K. Singh,  
808 Rajeev Sadanandan, Preeti Sudan, Balram Bhargava, and Nipah Investigators People  
809 and Health Study Group. 2019. "Outbreak Investigation of Nipah Virus Disease in  
810 Kerala, India, 2018." *The Journal of Infectious Diseases* 219 (12): 1867–78.
- 811 Assiri, Abdullah, Jaffar A. Al-Tawfiq, Abdullah A. Al-Rabeeah, Fahad A. Al-Rabiah, Sami Al-  
812 Hajjar, Ali Al-Barrak, Hesham Flemban, et al. 2013. "Epidemiological, Demographic, and  
813 Clinical Characteristics of 47 Cases of Middle East Respiratory Syndrome Coronavirus  
814 Disease from Saudi Arabia: A Descriptive Study." *The Lancet Infectious Diseases* 13 (9):  
815 752–61.
- 816 Assiri, Abdullah, Allison McGeer, Trish M. Perl, Connie S. Price, Abdullah A. Al Rabeeah, Derek  
817 A. T. Cummings, Zaki N. Alabdullatif, et al. 2013. "Hospital Outbreak of Middle East  
818 Respiratory Syndrome Coronavirus." *The New England Journal of Medicine* 369 (5):



- 819 407–16.
- 820 Bernasconi, Valentina, Paul A. Kristiansen, Mike Whelan, Raúl Gómez Román, Alison Bettis,  
821 Solomon Abebe Yimer, Céline Gurry, et al. 2020. “Developing Vaccines against  
822 Epidemic-Prone Emerging Infectious Diseases.” *Bundesgesundheitsblatt,  
823 Gesundheitsforschung, Gesundheitsschutz* 63 (1): 65–73.
- 824 Bird, Brian H., Thomas G. Ksiazek, Stuart T. Nichol, and N. James Maclachlan. 2009. “Rift  
825 Valley Fever Virus.” *Journal of the American Veterinary Medical Association* 234 (7):  
826 883–93.
- 827 Bob, Ndeye Sakha, Hampâté Bâ, Gamou Fall, Elkhailil Ishagh, Mamadou Y. Diallo,  
828 Abdourahmane Sow, Pape Mbacké Sembene, et al. 2017. “Detection of the  
829 Northeastern African Rift Valley Fever Virus Lineage During the 2015 Outbreak in  
830 Mauritania.” *Open Forum Infectious Diseases* 4 (2). <https://doi.org/10.1093/ofid/ofx087>.
- 831 Bowen, G. S., O. Tomori, H. Wulff, J. Casals, A. Noonan, and W. G. Downs. 1975. “Lassa Fever  
832 in Onitsha, East Central State, Nigeria in 1974.” *Bulletin of the World Health  
833 Organization* 52 (4–6): 599–604.
- 834 Breban, Romulus, Julien Riou, and Arnaud Fontanet. 2013. “Interhuman Transmissibility of  
835 Middle East Respiratory Syndrome Coronavirus: Estimation of Pandemic Risk.” *The  
836 Lancet* 382 (9893): 694–99.
- 837 Bron, Gebbiena M., Kathryn Strimbu, Helene Cecilia, Anita Lerch, Sean M. Moore, Quan Tran,  
838 T. Alex Perkins, and A. Quirine. 2021. “Over 100 Years of Rift Valley Fever: A Patchwork  
839 of Data on Pathogen Spread and Spillover.” *Pathogens* 10 (6): 708.
- 840 Brooks, Mollie E., Kasper Kristensen, Koen J. Van Benthem, Arni Magnusson, Casper W. Berg,  
841 Anders Nielsen, Hans J. Skaug, Martin Machler, and Benjamin M. Bolker. 2017.  
842 “GlmTMB Balances Speed and Flexibility among Packages for Zero-Inflated  
843 Generalized Linear Mixed Modeling.” *The R Journal* 9 (2): 378–400.
- 844 Bubar, Kate M., Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah Cobey, Yonatan H.  
845 Grad, and Daniel B. Larremore. 2021. “Model-Informed COVID-19 Vaccine Prioritization  
846 Strategies by Age and Serostatus.” *Science*. <https://doi.org/10.1126/science.abe6959>.
- 847 Carey, D. E., G. E. Kemp, H. A. White, L. Pinneo, R. F. Addy, A. L. Fom, G. Stroh, J. Casals,  
848 and B. E. Henderson. 1972. “Lassa Fever. Epidemiological Aspects of the 1970  
849 Epidemic, Jos, Nigeria.” *Transactions of the Royal Society of Tropical Medicine and  
850 Hygiene* 66 (3): 402–8.
- 851 Cauchemez, Simon, Christophe Fraser, Maria D. Van Kerkhove, Christl A. Donnelly, Steven  
852 Riley, Andrew Rambaut, Vincent Enouf, Sylvie van der Werf, and Neil M. Ferguson.  
853 2014. “Middle East Respiratory Syndrome Coronavirus: Quantification of the Extent of  
854 the Epidemic, Surveillance Biases, and Transmissibility.” *The Lancet Infectious Diseases*  
855 14 (1): 50–56.
- 856 Cauchemez, Simon, Pierre Nouvellet, Anne Cori, Thibaut Jombart, Tini Garske, Hannah  
857 Clapham, Sean Moore, et al. 2016. “Unraveling the Drivers of MERS-CoV  
858 Transmission.” *Proceedings of the National Academy of Sciences of the United States of  
859 America* 113 (32): 9081–86.
- 860 Centers for Disease Control and Prevention (CDC). 1998. “Rift Valley Fever -- East Africa,  
861 1997-1998.” *MMWR Morb Mortal Wkly Rep* 47 (13): 261–64.
- 862 ———. 2007. “Rift Valley Fever Outbreak --- Kenya, November 2006--January 2007.” *MMWR  
863 Morb Mortal Wkly Rep* 56 (4): 73–76.
- 864 ———. 2020. “Outbreak Summaries: Rift Valley Fever.” June 1, 2020.  
865 <https://www.cdc.gov/vhf/rvf/outbreaks/summaries.html>.
- 866 CEPI. 2018. “Priority Diseases – CEPI.” December 12, 2018.  
867 [https://cepi.net/research\\_dev/priority-diseases/](https://cepi.net/research_dev/priority-diseases/).
- 868 Chan, K. P., P. E. Rollin, T. G. Ksiazek, Y. S. Leo, K. T. Goh, N. I. Paton, E. H. Sng, and A. E.  
869 Ling. 2002a. “A Survey of Nipah Virus Infection among Various Risk Groups in



- 870 Singapore." *Epidemiology and Infection* 128 (1): 93–98.
- 871 ———. 2002b. "A Survey of Nipah Virus Infection among Various Risk Groups in Singapore."
- 872 *Epidemiology & Infection* 128 (1): 93–98.
- 873 Chowell, Gerardo, Seth Blumberg, Lone Simonsen, Mark A. Miller, and Cécile Viboud. 2014.
- 874 "Synthesizing Data and Models for the Spread of MERS-CoV, 2013: Key Role of Index
- 875 Cases and Hospital Transmission." *Epidemics* 9 (December): 40–51.
- 876 CSR. n.d. "World Health Organization - Eastern Mediterranean Region." Accessed March 19,
- 877 2019. [http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-](http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-february-2019.html)
- 878 [update-february-2019.html](http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-february-2019.html).
- 879 Daubney, R., J. R. Hudson, and P. C. Garnham. 1931. "Enzootic Hepatitis or Rift Valley Fever.
- 880 An Undescribed Virus Disease of Sheep Cattle and Man from East Africa." *The Journal*
- 881 *of Pathology and Bacteriology* 34 (4): 545–79.
- 882 Dudas, Gytis, Luiz Max Carvalho, Andrew Rambaut, and Trevor Bedford. 2018. "MERS-CoV
- 883 Spillover at the Camel-Human Interface." *ELife* 7 (January).
- 884 <https://doi.org/10.7554/eLife.31257>.
- 885 E Keane, H. M. Gilles. 1977. "Lassa Fever in Panguma Hospital, Sierra Leone, 1973-6." *British*
- 886 *Medical Journal* 1 (6073): 1399.
- 887 Excler, Jean-Louis, Melanie Saville, Seth Berkley, and Jerome H. Kim. 2021. "Vaccine
- 888 Development for Emerging Infectious Diseases." *Nature Medicine* 27 (4): 591–600.
- 889 FAO. 2017. "Rift Valley Fever in Niger: Risk Assessment."
- 890 <http://www.fao.org/3/i7055e/i7055e.pdf>.
- 891 Farrington, C. P., M. N. Kanaan, and N. J. Gay. 2003. "Branching Process Models for
- 892 Surveillance of Infectious Diseases Controlled by Mass Vaccination." *Biostatistics* 4 (2):
- 893 279–95.
- 894 Faye, Ousmane, Mawlouth Diallo, Djibril Diop, O. Elmamy Bezeid, Hampathé Bâ, Mbayame
- 895 Niang, Ibrahima Dia, et al. 2007. "Rift Valley Fever Outbreak with East-Central African
- 896 Virus Lineage in Mauritania, 2003." *Emerging Infectious Diseases* 13 (7): 1016.
- 897 Findlay, G. M. 1932. "Rift Valley Fever or Enzootic Hepatitis." *Transactions of the Royal Society*
- 898 *of Tropical Medicine and Hygiene* 25 (4): 229-IN11.
- 899 Fisher-Hoch, S. P., O. Tomori, A. Nasidi, G. I. Perez-Oronoz, Y. Fakile, L. Hutwagner, and J. B.
- 900 McCormick. 1995. "Review of Cases of Nosocomial Lassa Fever in Nigeria: The High
- 901 Price of Poor Medical Practice." *BMJ* 311 (7009): 857–59.
- 902 Frame, J. D., J. M. Baldwin Jr, D. J. Gocke, and J. M. Troup. 1970. "Lassa Fever, a New Virus
- 903 Disease of Man from West Africa. I. Clinical Description and Pathological Findings." *The*
- 904 *American Journal of Tropical Medicine and Hygiene* 19 (4): 670–76.
- 905 Francis, T., and T. P. Magill. 1935. "RIFT VALLEY FEVER : A REPORT OF THREE CASES OF
- 906 LABORATORY INFECTION AND THE EXPERIMENTAL TRANSMISSION OF THE
- 907 DISEASE TO FERRETS." *The Journal of Experimental Medicine* 62 (3): 433–48.
- 908 Fraser, D. W., C. C. Campbell, T. P. Monath, P. A. Goff, and M. B. Gregg. 1974. "Lassa Fever
- 909 in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic Studies." *The*
- 910 *American Journal of Tropical Medicine and Hygiene* 23 (6): 1131–39.
- 911 Gerken, Keli N., A. Desiree LaBeaud, Henshaw Mandi, Maina L'Azou Jackson, J. Gabrielle
- 912 Breugelmans, and Charles H. King. 2021. "Paving the Way for Human Vaccination
- 913 against Rift Valley Fever Virus: 1 A Systematic Literature Review of RVFV Epidemiology
- 914 from 1999 to 2021." *MedRxiv*. <https://doi.org/10.1101/2021.09.29.21264307>.
- 915 Gibb, Rory, Lina M. Moses, David W. Redding, and Kate E. Jones. 2017. "Understanding the
- 916 Cryptic Nature of Lassa Fever in West Africa." *Pathogens and Global Health* 111 (6):
- 917 276–88.
- 918 Girish Kumar, C. P., Attayur P. Sugunan, Pragya Yadav, Karishma Krishna Kurup, Renjith
- 919 Aarathie, Ponnaiah Manickam, Tarun Bhatnagar, et al. 2019. "Infections among
- 920 Contacts of Patients with Nipah Virus, India." *Emerging Infectious Diseases Journal* 25

- 921 (5). <https://doi.org/10.3201/eid2505.181352>.
- 922 Gouglas, Dimitrios, Mario Christodoulou, Stanley A. Plotkin, and Richard Hatchett. 2019. "CEPI:  
923 Driving Progress Toward Epidemic Preparedness and Response." *Epidemiologic*  
924 *Reviews* 41 (1): 28–33.
- 925 Grange, Zoë L., Tracey Goldstein, Christine K. Johnson, Simon Anthony, Kirsten Gilardi, Peter  
926 Daszak, Kevin J. Olival, et al. 2021. "Ranking the Risk of Animal-to-Human Spillover for  
927 Newly Discovered Viruses." *Proceedings of the National Academy of Sciences of the*  
928 *United States of America* 118 (15). <https://doi.org/10.1073/pnas.2002324118>.
- 929 Group, The Who Mers-Cov Research, and The WHO MERS-CoV Research Group. 2013.  
930 "State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus  
931 (MERS-CoV) in Humans." *PLoS Currents*.  
932 <https://doi.org/10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8>.
- 933 Gurley, Emily S., Joel M. Montgomery, M. Jahangir Hossain, Michael Bell, Abul Kalam Azad,  
934 Mohammed Rafiqul Islam, Mohammed Abdur Rahim Molla, et al. 2007. "Person-to-  
935 Person Transmission of Nipah Virus in a Bangladeshi Community." *Emerging Infectious*  
936 *Diseases* 13 (7): 1031–37.
- 937 Gurley, Emily S., Joel M. Montgomery, M. Jahangir Hossain, M. Rafiqul Islam, M. Abdur Rahim  
938 Molla, S. M. Shamsuzzaman, Kazi Akram, et al. 2007. "Risk of Nosocomial  
939 Transmission of Nipah Virus in a Bangladesh Hospital." *Infection Control and Hospital*  
940 *Epidemiology: The Official Journal of the Society of Hospital Epidemiologists of America*  
941 28 (6): 740–42.
- 942 Hamblion, E. L., P. Raftery, A. Wendland, E. Dweh, G. S. Williams, R. N. C. George, L. Soro, et  
943 al. 2018. "The Challenges of Detecting and Responding to a Lassa Fever Outbreak in an  
944 Ebola-Affected Setting." *International Journal of Infectious Diseases: IJID: Official*  
945 *Publication of the International Society for Infectious Diseases* 66 (January): 65–73.
- 946 Henao-Restrepo, Ana Maria, Anton Camacho, Ira M. Longini, Conall H. Watson, W. John  
947 Edmunds, Matthias Egger, Miles W. Carroll, et al. 2017. "Efficacy and Effectiveness of  
948 an RVS-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the  
949 Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)." *The*  
950 *Lancet*. [https://doi.org/10.1016/s0140-6736\(16\)32621-6](https://doi.org/10.1016/s0140-6736(16)32621-6).
- 951 Hoogstraal, H., J. M. Meegan, G. M. Khalil, and F. K. Adham. 1979. "The Rift Valley Fever  
952 Epizootic in Egypt 1977-78. 2. Ecological and Entomological Studies." *Transactions of*  
953 *the Royal Society of Tropical Medicine and Hygiene* 73 (6): 624–29.
- 954 Hsu, Vincent P., Mohammed Jahangir Hossain, Umesh D. Parashar, Mohammed Monsur Ali,  
955 Thomas G. Ksiazek, Ivan Kuzmin, Michael Niezgod, Charles Rupprecht, Joseph  
956 Bresee, and Robert F. Breiman. 2004. "Nipah Virus Encephalitis Reemergence,  
957 Bangladesh." *Emerging Infectious Diseases* 10 (12): 2082–87.
- 958 Hui, David S., Esam I. Azhar, Yae-Jean Kim, Ziad A. Memish, Myoung-Don Oh, and Alimuddin  
959 Zumla. 2018. "Middle East Respiratory Syndrome Coronavirus: Risk Factors and  
960 Determinants of Primary, Household, and Nosocomial Transmission." *The Lancet*  
961 *Infectious Diseases* 18 (8): e217–27.
- 962 Huneycutt, Brenda, Nicole Lurie, Sara Rotenberg, Richard Wilder, and Richard Hatchett. 2020.  
963 "Finding Equipose: CEPI Revises Its Equitable Access Policy." *Vaccine* 38 (9): 2144–  
964 48.
- 965 Islam, M. Saiful, Hossain M. S. Sazzad, Syed Moinuddin Satter, Sharmin Sultana, M. Jahangir  
966 Hossain, Murshid Hasan, Mahmudur Rahman, et al. 2016. "Nipah Virus Transmission  
967 from Bats to Humans Associated with Drinking Traditional Liquor Made from Date Palm  
968 Sap, Bangladesh, 2011-2014." *Emerging Infectious Diseases* 22 (4): 664–70.
- 969 Jouan, A., B. Le Guenno, J. P. Digoutte, B. Philippe, O. Riou, and F. Adam. 1988. "An RVF  
970 Epidemic in Southern Mauritania." *Annales de l'Institut Pasteur. Virology* 139 (3).  
971 [https://doi.org/10.1016/s0769-2617\(88\)80046-7](https://doi.org/10.1016/s0769-2617(88)80046-7).

- 972 Kernéis, Solen, Lamine Koivogui, N'faly Magassouba, Kekoura Koulemou, Rosamund Lewis,  
973 Aristide Aplogan, Rebecca F. Grais, Philippe J. Guerin, and Elisabeth Fichet-Calvet.  
974 2009. "Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest  
975 Region of Guinea: A Cross-Sectional Study." *PLoS Neglected Tropical Diseases*.  
976 <https://doi.org/10.1371/journal.pntd.0000548>.
- 977 Khan, S. H., A. Goba, M. Chu, C. Roth, T. Healing, A. Marx, J. Fair, et al. 2008. "New  
978 Opportunities for Field Research on the Pathogenesis and Treatment of Lassa Fever."  
979 *Antiviral Research* 78 (1): 103–15.
- 980 Ki, Moran. 2015. "2015 MERS Outbreak in Korea: Hospital-to-Hospital Transmission."  
981 *Epidemiology and Health* 37 (July): e2015033.
- 982 Kitchen, S. F. 1934. "Laboratory Infections with the Virus of Rift Valley Fever 1." *The American  
983 Journal of Tropical Medicine and Hygiene* s1-14 (6): 547–64.
- 984 Kucharski, A. J., and C. L. Althaus. 2015. "The Role of Superspreading in Middle East  
985 Respiratory Syndrome Coronavirus (MERS-CoV) Transmission." *Euro Surveillance:  
986 Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease  
987 Bulletin* 20 (25): 14–18.
- 988 Kumar, C. P. Girish, Attayur P. Sugunan, Pragya Yadav, Karishma Krishna Kurup, Renjith  
989 Aarathie, Ponnaiah Manickam, Tarun Bhatnagar, et al. 2019. "Infections among  
990 Contacts of Patients with Nipah Virus, India." *Emerging Infectious Diseases* 25 (5):  
991 1007–10.
- 992 Laughlin, Larry W., James M. Meegan, Larry J. Strausbaugh, David M. Morens, and Raymond  
993 H. Watten. 1979. "Epidemic Rift Valley Fever in Egypt: Observations of the Spectrum of  
994 Human Illness." *Transactions of the Royal Society of Tropical Medicine and Hygiene* 73  
995 (6): 630–33.
- 996 Lee, Elizabeth C., Nikolas I. Wada, M. Kate Grabowski, Emily S. Gurley, and Justin Lessler.  
997 2020. "The Engines of SARS-CoV-2 Spread." *Science* 370 (6515): 406–7.
- 998 Linthicum, Kenneth J., Seth C. Britch, and Assaf Anyamba. 2016. "Rift Valley Fever: An  
999 Emerging Mosquito-Borne Disease." *Annual Review of Entomology* 61: 395–415.
- 1000 Lo Iacono, G., A. A. Cunningham, E. Fichet-Calvet, R. F. Garry, D. S. Grant, S. H. Khan, M.  
1001 Leach, et al. 2015. "Using Modelling to Disentangle the Relative Contributions of  
1002 Zoonotic and Anthroponotic Transmission: The Case of Lassa Fever." *PLoS Neglected  
1003 Tropical Diseases* 9 (1). <https://doi.org/10.1371/journal.pntd.0003398>.
- 1004 Luby, Stephen P., M. Jahangir Hossain, Emily S. Gurley, Be Nazir Ahmed, Shakila Banu, Salah  
1005 Uddin Khan, Nusrat Homaira, et al. 2009. "Recurrent Zoonotic Transmission of Nipah  
1006 Virus into Humans, Bangladesh, 2001-2007." *Emerging Infectious Diseases* 15 (8):  
1007 1229–35.
- 1008 Maina, Joseph, Paul O. Ouma, Peter M. Macharia, Victor A. Alegana, Benard Mitto, Ibrahim  
1009 Socé Fall, Abdisalan M. Noor, Robert W. Snow, and Emelda A. Okiro. 2019. "A Spatial  
1010 Database of Health Facilities Managed by the Public Health Sector in Sub Saharan  
1011 Africa." *Scientific Data* 6 (1): 134.
- 1012 McCormick, J. B., P. A. Webb, J. W. Krebs, K. M. Johnson, and E. S. Smith. 1987. "A  
1013 Prospective Study of the Epidemiology and Ecology of Lassa Fever." *The Journal of  
1014 Infectious Diseases* 155 (3): 437–44.
- 1015 Medlock, Jan, and Alison P. Galvani. 2009. "Optimizing Influenza Vaccine Distribution." *Science*  
1016 325 (5948): 1705–8.
- 1017 "MERS-CoV Cases." n.d. Accessed December 4, 2020. [http://rambaut.github.io/MERS-  
1018 Tools/cases2.html](http://rambaut.github.io/MERS-Tools/cases2.html).
- 1019 Métras, Raphaëlle, Lisa Cavalerie, Laure Dommergues, Philippe Mérot, W. John Edmunds,  
1020 Matt J. Keeling, Catherine Cêtre-Sossah, and Eric Cardinale. 2016. "The Epidemiology  
1021 of Rift Valley Fever in Mayotte: Insights and Perspectives from 11 Years of Data." *PLoS  
1022 Neglected Tropical Diseases* 10 (6). <https://doi.org/10.1371/journal.pntd.0004783>.

- 1023 Meulen, J. ter, O. Lenz, L. Koivogui, N. Magassouba, S. K. Kaushik, R. Lewis, and W. Aldis.  
1024 2001. "Short Communication: Lassa Fever in Sierra Leone: UN Peacekeepers Are at  
1025 Risk." *Tropical Medicine & International Health: TM & IH* 6 (1): 83–84.  
1026 "Ministry of Health - Kingdom of Saudi Arabia." 2020. 2020.  
1027 <https://www.moh.gov.sa/en/CCC/events/national/Pages/2020.aspx>.  
1028 Monath, T. P. 1974. "Lassa Fever and Marburg Virus Disease." *WHO Chronicle* 28 (5).  
1029 <https://pubmed.ncbi.nlm.nih.gov/4208764/>.  
1030 Monath, T. P., P. E. Mertens, R. Patton, C. R. Moser, J. J. Baum, L. Pinneo, G. W. Gary, and R.  
1031 E. Kissling. 1973. "A Hospital Epidemic of Lassa Fever in Zorzor, Liberia, March-April  
1032 1972." *The American Journal of Tropical Medicine and Hygiene* 22 (6): 773–79.  
1033 Morse, Stephen S., Jonna A. K. Mazet, Mark Woolhouse, Colin R. Parrish, Dennis Carroll,  
1034 William B. Karesh, Carlos Zambrana-Torrel, W. Ian Lipkin, and Peter Daszak. 2012.  
1035 "Prediction and Prevention of the next Pandemic Zoonosis." *The Lancet* 380 (9857):  
1036 1956–65.  
1037 Msimang, Veerle, Peter N. Thompson, Petrus Jansen van Vuren, Stefano Tempia, Claudia  
1038 Cordel, Joe Kgaladi, Jimmy Khosa, et al. 2019. "Rift Valley Fever Virus Exposure  
1039 amongst Farmers, Farm Workers, and Veterinary Professionals in Central South Africa."  
1040 *Viruses* 11 (2). <https://doi.org/10.3390/v11020140>.  
1041 Müller, Marcel A., Benjamin Meyer, Victor M. Corman, Malak Al-Masri, Abdulhafeez Turkestani,  
1042 Daniel Ritz, Andrea Sieberg, et al. 2015. "Presence of Middle East Respiratory  
1043 Syndrome Coronavirus Antibodies in Saudi Arabia: A Nationwide, Cross-Sectional,  
1044 Serological Study." *The Lancet Infectious Diseases*. [https://doi.org/10.1016/s1473-](https://doi.org/10.1016/s1473-3099(15)70090-3)  
1045 [3099\(15\)70090-3](https://doi.org/10.1016/s1473-3099(15)70090-3).  
1046 Mundel, B., and J. Gear. 1951. "Rift Valley Fever; I. The Occurrence of Human Cases in  
1047 Johannesburg." *South African Medical Journal = Suid-Afrikaanse Tydskrif Vir*  
1048 *Geneeskunde* 25 (44): 797–800.  
1049 Munyua, Peninah M., Isaac Ngere, Elizabeth Hunsperger, Adano Kochi, Patrick Amoth, Lydia  
1050 Mwasi, Suxiang Tong, et al. 2021. "Low-Level Middle East Respiratory Syndrome  
1051 Coronavirus among Camel Handlers, Kenya, 2019." *Emerging Infectious Diseases* 27  
1052 (4): 1201–5.  
1053 Mylne, Adrian Q. N., David M. Pigott, Joshua Longbottom, Freya Shearer, Kirsten A. Duda,  
1054 Jane P. Messina, Daniel J. Weiss, Catherine L. Moyes, Nick Golding, and Simon I. Hay.  
1055 2015. "Mapping the Zoonotic Niche of Lassa Fever in Africa." *Transactions of the Royal*  
1056 *Society of Tropical Medicine and Hygiene* 109 (8): 483–92.  
1057 Nderitu, Leonard, John S. Lee, Jared Omolo, Sylvia Omulo, Monica L. O'Guinn, Allen  
1058 Hightower, Fausta Mosha, et al. 2010. "Sequential Rift Valley Fever Outbreaks in  
1059 Eastern Africa Caused by Multiple Lineages of the Virus." *The Journal of Infectious*  
1060 *Diseases* 203 (5): 655–65.  
1061 "Nigeria Centre for Disease Control." n.d. Accessed December 31, 2020.  
1062 <https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria>.  
1063  
1064 Nikolay, Birgit. 2019. "Transmission of Nipah Virus - 14 Years of Investigations in Bangladesh."  
1065 *The New England Journal of Medicine* 380 (19): 1804–14.  
1066 Nikolay, Birgit, Henrik Salje, M. Jahangir Hossain, A. K. M. Dawlat Khan, Hossain M. S. Sazzad,  
1067 Mahmudur Rahman, Peter Daszak, Ute Ströher, Juliet R. C. Pulliam, A. Marm Kilpatrick,  
1068 Stuart T. Nichol, et al. 2019. "Transmission of Nipah Virus - 14 Years of Investigations in  
1069 Bangladesh." *The New England Journal of Medicine* 380 (19): 1804–14.  
1070 Nikolay, Birgit, Henrik Salje, M. Jahangir Hossain, Akm Dawlat Khan, Hossain M. S. Sazzad,  
1071 Mahmudur Rahman, Peter Daszak, Ute Ströher, Juliet R. C. Pulliam, A. Marm Kilpatrick,  
1072 and Others. 2019. "Transmission of Nipah Virus—14 Years of Investigations in  
1073 Bangladesh." *The New England Journal of Medicine* 380 (19): 1804–14.



- 1074 Nyakarahuka, Luke, Annabelle de St Maurice, Lawrence Purpura, Elizabeth Ervin, Stephen  
1075 Balinandi, Alex Tumusiime, Jackson Kyondo, et al. 2018. "Prevalence and Risk Factors  
1076 of Rift Valley Fever in Humans and Animals from Kabale District in Southwestern  
1077 Uganda, 2016." *PLoS Neglected Tropical Diseases* 12 (5): e0006412.
- 1078 O'Hearn, Aileen E., Matthew A. Voorhees, David P. Fetterer, Nadia Wauquier, Moinya R.  
1079 Coomber, James Bangura, Joseph N. Fair, Jean-Paul Gonzalez, and Randal J.  
1080 Schoepp. 2016. "Serosurveillance of Viral Pathogens Circulating in West Africa."  
1081 *Virology Journal* 13 (1): 163.
- 1082 Overbosch, Femke, Mark de Boer, Karin Ellen Veldkamp, Pauline Ellerbroek, Chantal P.  
1083 Bleeker-Rovers, Bram Goorhuis, Michele van Vugt, et al. 2020. "Public Health Response  
1084 to Two Imported, Epidemiologically Related Cases of Lassa Fever in the Netherlands  
1085 (Ex Sierra Leone), November 2019." *Euro Surveillance: Bulletin Europeen Sur Les  
1086 Maladies Transmissibles = European Communicable Disease Bulletin* 25 (15).  
1087 <https://doi.org/10.2807/1560-7917.ES.2020.25.15.2000265>.
- 1088 Parashar, U. D., L. M. Sunn, F. Ong, A. W. Mounts, M. T. Arif, T. G. Ksiazek, M. A. Kamaluddin,  
1089 et al. 2000. "Case-Control Study of Risk Factors for Human Infection with a New  
1090 Zoonotic Paramyxovirus, Nipah Virus, during a 1998-1999 Outbreak of Severe  
1091 Encephalitis in Malaysia." *The Journal of Infectious Diseases* 181 (5): 1755–59.
- 1092 Park, Sun Hee, Yeon-Sook Kim, Younghee Jung, Soo Young Choi, Nam-Hyuk Cho, Hye Won  
1093 Jeong, Jung Yeon Heo, et al. 2016. "Outbreaks of Middle East Respiratory Syndrome in  
1094 Two Hospitals Initiated by a Single Patient in Daejeon, South Korea." *Infection &  
1095 Chemotherapy* 48 (2): 99–107.
- 1096 Pepin, Michel, Michele Bouloy, Brian H. Bird, Alan Kemp, and Janusz Paweska. 2010. "Rift  
1097 Valley Fever Virus(Bunyaviridae: Phlebovirus): An Update on Pathogenesis, Molecular  
1098 Epidemiology, Vectors, Diagnostics and Prevention." *Veterinary Research* 41 (6): 61.
- 1099 Poletto, C., C. Pelat, D. Levy-Bruhl, Y. Yazdanpanah, P. Y. Boelle, and V. Colizza. 2014.  
1100 "Assessment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)  
1101 Epidemic in the Middle East and Risk of International Spread Using a Novel Maximum  
1102 Likelihood Analysis Approach." *Euro Surveillance: Bulletin Europeen Sur Les Maladies  
1103 Transmissibles = European Communicable Disease Bulletin* 19 (23).  
1104 <https://doi.org/10.2807/1560-7917.es2014.19.23.20824>.
- 1105 ProMED-mail. 2020. "ProMED-Mail." 2020. <https://promedmail.org/>.
- 1106 Pulliam, Juliet R. C., Jonathan H. Epstein, Jonathan Dushoff, Sohayati A. Rahman, Michel  
1107 Bunning, Aziz A. Jamaluddin, Alex D. Hyatt, et al. 2012. "Agricultural Intensification,  
1108 Priming for Persistence and the Emergence of Nipah Virus: A Lethal Bat-Borne  
1109 Zoonosis." *Journal of the Royal Society, Interface / the Royal Society* 9 (66): 89–101.
- 1110 Rahman, Muhammad Aziz, Mohammad Jahangir Hossain, Sharmin Sultana, Nusrat Homaira,  
1111 Salah Uddin Khan, Mahmudur Rahman, Emily S. Gurley, et al. 2012. "Date Palm Sap  
1112 Linked to Nipah Virus Outbreak in Bangladesh, 2008." *Vector Borne and Zoonotic  
1113 Diseases* 12 (1): 65–72.
- 1114 Reeves, Tarian, Abdallah M. Samy, and A. Townsend Peterson. 2015. "MERS-CoV Geography  
1115 and Ecology in the Middle East: Analyses of Reported Camel Exposures and a  
1116 Preliminary Risk Map." *BMC Research Notes* 8 (1): 1–7.
- 1117 "Rift Valley Fever in Egypt and Other African Countries: Historical Review, Recent Outbreaks  
1118 and Possibility of Disease Occurrence in Egypt." 2018. *Acta Tropica* 181 (May): 40–49.
- 1119 Roberts, Leslie. 2018. "Nigeria Hit by Unprecedented Lassa Fever Outbreak." *Science* 359  
1120 (6381): 1201–2.
- 1121 Røttingen, John-Arne, Dimitrios Gouglas, Mark Feinberg, Stanley Plotkin, Krishnaswamy V.  
1122 Raghavan, Andrew Witty, Ruxandra Draghia-Akli, Paul Stoffels, and Peter Piot. 2017.  
1123 "New Vaccines against Epidemic Infectious Diseases." *The New England Journal of  
1124 Medicine* 376 (7): 610–13.

- 1125 Saameli, René, Dikolela Kalubi, Mark Herringer, Tim Sutton, and Eric de Roodenbeke. 2018.  
1126 “Healthsites.io: The Global Healthsites Mapping Project.” *Technologies for*  
1127 *Development*. [https://doi.org/10.1007/978-3-319-91068-0\\_5](https://doi.org/10.1007/978-3-319-91068-0_5).
- 1128 Sabin, A. B., and R. W. Blumberg. 1947. “Human Infection with Rift Valley Fever Virus and  
1129 Immunity Twelve Years after Single Attack.” *Proceedings of the Society for Experimental*  
1130 *Biology and Medicine*. *Society for Experimental Biology and Medicine* 64 (4): 385–89.
- 1131 Sha, Jianping, Yuan Li, Xiaowen Chen, Yan Hu, Yajin Ren, Xingyi Geng, Zhiruo Zhang, and  
1132 Shelan Liu. 2017. “Fatality Risks for Nosocomial Outbreaks of Middle East Respiratory  
1133 Syndrome Coronavirus in the Middle East and South Korea.” *Archives of Virology* 162  
1134 (1): 33–44.
- 1135 Sheahan, Timothy, Barry Rockx, Eric Donaldson, Amy Sims, Raymond Pickles, Davide Corti,  
1136 and Ralph Baric. 2008. “Mechanisms of Zoonotic Severe Acute Respiratory Syndrome  
1137 Coronavirus Host Range Expansion in Human Airway Epithelium.” *Journal of Virology* 82  
1138 (5): 2274–85.
- 1139 Siddle, Katherine J., Philomena Eromon, Kayla G. Barnes, Samar Mehta, Judith U. Oguzie,  
1140 Ikponmwoza Oda, Stephen F. Schaffner, et al. 2018. “Genomic Analysis of Lassa Virus  
1141 during an Increase in Cases in Nigeria in 2018.” *The New England Journal of Medicine*  
1142 379 (18): 1745–53.
- 1143 Sissoko, Daouda, Claude Giry, Philippe Gabrie, Arnaud Tarantola, François Pettinelli, Louis  
1144 Collet, Eric D’Ortenzio, Philippe Renault, and Vincent Pierre. 2009. “Rift Valley Fever,  
1145 Mayotte, 2007–2008.” *Emerging Infectious Diseases* 15 (4): 568.
- 1146 Smithburn, K. C., and A. F. Mahaffy. 1949. “Rift Valley Fever; Accidental Infections among  
1147 Laboratory Workers.” *Journal of Immunology* 62 (2): 213–27.
- 1148 Sow, Abdourahmane, Ousmane Faye, Yamar Ba, Hampathé Ba, Diawo Diallo, Oumar Faye,  
1149 Cheikh Loucoubar, et al. 2014. “Rift Valley Fever Outbreak, Southern Mauritania, 2012.”  
1150 *Emerging Infectious Diseases* 20 (2): 296.
- 1151 Sow, Abdourahmane, Ousmane Faye, Yamar Ba, Diawo Diallo, Gamou Fall, Oumar Faye,  
1152 Ndeye Sakha Bob, et al. 2016. “Widespread Rift Valley Fever Emergence in Senegal in  
1153 2013–2014.” *Open Forum Infectious Diseases* 3 (3). <https://doi.org/10.1093/ofid/ofw149>.
- 1154 Tan, Kay-Sin, Chong Tin Tan, and Khean Jin Goh. 1999. “Epidemiological Aspects of Nipah  
1155 Virus Infection.” *Neurol J Southeast Asia* 4 (1): 77–81.
- 1156 Tatem, Andrew J. 2017. “WorldPop, Open Data for Spatial Demography.” *Scientific Data* 4  
1157 (January): 170004.
- 1158 Tindale, Lauren C., Jessica E. Stockdale, Michelle Coombe, Emma S. Garlock, Wing Yin Venus  
1159 Lau, Manu Saraswat, Louxin Zhang, Dongxuan Chen, Jacco Wallinga, and Caroline  
1160 Colijn. 2020. “Evidence for Transmission of COVID-19 Prior to Symptom Onset.” *ELife* 9  
1161 (June). <https://doi.org/10.7554/eLife.57149>.
- 1162 Virlogeux, Victor, Minah Park, Joseph T. Wu, and Benjamin J. Cowling. 2016. “Association  
1163 between Severity of MERS-CoV Infection and Incubation Period.” *Emerging Infectious*  
1164 *Diseases* 22 (3): 526–28.
- 1165 WHO. 2016. “Prioritizing Diseases for Research and Development in Emergency Contexts.”  
1166 2016. [https://www.who.int/activities/prioritizing-diseases-for-research-and-development-](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)  
1167 [in-emergency-contexts](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts).
- 1168 ———. 2017a. “WHO Target Product Profile for Lassa Virus Vaccine.”  
1169 [https://www.who.int/blueprint/priority-diseases/key-](https://www.who.int/blueprint/priority-diseases/key-action/LassaVirusVaccineTPP.PDF?ua=1)  
1170 [action/LassaVirusVaccineTPP.PDF?ua=1](https://www.who.int/blueprint/priority-diseases/key-action/LassaVirusVaccineTPP.PDF?ua=1).
- 1171 ———. 2017b. “WHO Target Product Profile for Nipah Virus Vaccine.”  
1172 [https://www.who.int/blueprint/priority-diseases/key-action/Nipah\\_virus\\_vaccineTPP.pdf](https://www.who.int/blueprint/priority-diseases/key-action/Nipah_virus_vaccineTPP.pdf).
- 1173 ———. 2017c. “WHO Target Product Profiles for MERS-CoV Vaccines.”  
1174 [https://www.who.int/blueprint/what/research-](https://www.who.int/blueprint/what/research-development/MERS_CoV_TPP_15052017.pdf?ua=1)  
1175 [development/MERS\\_CoV\\_TPP\\_15052017.pdf?ua=1](https://www.who.int/blueprint/what/research-development/MERS_CoV_TPP_15052017.pdf?ua=1).



- 1176 ———. 2018. “Weekly Bulletin on Outbreaks and Other Emergencies.” 2018.  
1177 <https://apps.who.int/iris/bitstream/handle/10665/273028/OEW27-300606072018.pdf>.  
1178 ———. 2019. “Target Product Profiles for Rift Valley Fever Virus Vaccines.”  
1179 [https://www.who.int/docs/default-source/blue-print/call-for-comments/tpp-rift-valley-fever-](https://www.who.int/docs/default-source/blue-print/call-for-comments/tpp-rift-valley-fever-vaccines-draft3-0pc.pdf?sfvrsn=f2f3b314_2)  
1180 [vaccines-draft3-0pc.pdf?sfvrsn=f2f3b314\\_2](https://www.who.int/docs/default-source/blue-print/call-for-comments/tpp-rift-valley-fever-vaccines-draft3-0pc.pdf?sfvrsn=f2f3b314_2).  
1181 ———. 2020. “WHO Coronavirus (COVID-19) Dashboard.” 2020. <https://covid19.who.int/>.  
1182 ———. 2021. “THE GLOBAL HEALTH OBSERVATORY.” 2021.  
1183 [https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-](https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/sdg-target-3.c-health-workforce)  
1184 [details/GHO/sdg-target-3.c-health-workforce](https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/sdg-target-3.c-health-workforce).  
1185 “WHO | Rift Valley Fever – Gambia.” 2018, February. [http://www.who.int/csr/don/26-february-](http://www.who.int/csr/don/26-february-2018-rift-valley-fever-gambia/en/)  
1186 [2018-rift-valley-fever-gambia/en/](http://www.who.int/csr/don/26-february-2018-rift-valley-fever-gambia/en/).  
1187 Wilson, M. L., L. E. Chapman, D. B. Hall, E. A. Dykstra, K. Ba, H. G. Zeller, M. Traore-  
1188 Lamizana, J. P. Hervy, K. J. Linthicum, and C. J. Peters. 1994. “Rift Valley Fever in  
1189 Rural Northern Senegal: Human Risk Factors and Potential Vectors.” *The American*  
1190 *Journal of Tropical Medicine and Hygiene* 50 (6): 663–75.  
1191 Woods, Christopher W., Adam M. Karpati, Thomas Grein, Noel McCarthy, Peter Gaturuku, Eric  
1192 Muchiri, Lee Dunster, et al. 2002. “An Outbreak of Rift Valley Fever in Northeastern  
1193 Kenya, 1997-98.” *Emerging Infectious Diseases* 8 (2): 138.  
1194 Yen, Catherine, Terri B. Hyde, Alejandro J. Costa, Katya Fernandez, John S. Tam, Stéphane  
1195 Hugonnet, Anne M. Huvos, Philippe Duclos, Vance J. Dietz, and Brenton T. Burkholder.  
1196 2015. “The Development of Global Vaccine Stockpiles.” *The Lancet Infectious Diseases*  
1197 15 (3): 340–47.  
1198 Yob, J. M., H. Field, A. M. Rashdi, C. Morrissy, B. van der Heide, P. Rota, A. bin Adzhar, et al.  
1199 2001. “Nipah Virus Infection in Bats (Order Chiroptera) in Peninsular Malaysia.”  
1200 *Emerging Infectious Diseases* 7 (3): 439–41.  
1201 Youssouf, Hassani, Marion Subiros, Genevieve Denetiere, Louis Collet, Laure Dommergues,  
1202 Amandine Pauvert, Patrick Rabarison, et al. 2020. “Rift Valley Fever Outbreak, Mayotte,  
1203 France, 2018–2019.” *Emerging Infectious Diseases* 26 (4): 769.  
1204

1205 **Supplementary Information**

1206

1207 **Table of Contents**

1208


|      |  |    |
|------|--|----|
| 1209 | Table S1 .....   | 35 |
| 1210 | Figures S1-S4 .....  | 36 |
| 1211 | SI Text .....  | 40 |
| 1212 | 1. Sensitivity analysis: Reactive vaccination strategies ..... | 40 |
| 1213 | 2. Sensitivity analysis: $R_0$ .....                           | 41 |
| 1214 | 3. Model limitations .....                                     | 41 |
| 1215 | Figures S5-S34 .....   | 45 |

1216 **Table S1. Overview of data references.**


| Parameter         | LASV             | MERS-CoV         | NiV              | RVFV             |
|-------------------|------------------|------------------|------------------|------------------|
| Case reports      | 1-11             | 11-15            | 11,16-22         | 11,23-43         |
| Seasonality       | See case reports | See case reports | See case reports | See case reports |
| Incubation period | 44-47            | 48-51            | 52               | 53-60            |
| Infectious period | 47               | 48,51,61,62      | 63               | 64               |
| R <sub>0</sub>    | 65               | 49, 66-70        | 52               |                  |

1217 1 (“Nigeria Centre for Disease Control” n.d.), 2 (Carey et al. 1972), 3 (Monath et al. 1973), 4 (Bowen et al.  
1218 1975), 5 (E Keane 1977), 6 (ter Meulen et al. 2001), 7 (Ajayi 2013), 8 (Fisher-Hoch et al. 1995), 9 (Fraser  
1219 et al. 1974), 10 (Hamblion et al. 2018), 11 (ProMED-mail 2020), 12 (“MERS-CoV Cases” n.d.), 13  
1220 (“Ministry of Health - Kingdom of Saudi Arabia” 2020), 14 (Reeves, Samy, and Townsend Peterson  
1221 2015), 15 <http://rambaut.github.io/MERS-Tools/cases2.html>, 16 (Hsu et al. 2004), 17 (Gurley,  
1222 Montgomery, Hossain, Islam, et al. 2007), 18 (Kumar et al. 2019), 19 (Nikolay, Salje, Hossain, Khan,  
1223 Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019), 20 (Tan, Tan, and Goh 1999),  
1224 21 (Parashar et al. 2000), 22 (Chan et al. 2002a), 23 (“Rift Valley Fever in Egypt and Other African  
1225 Countries: Historical Review, Recent Outbreaks and Possibility of Disease Occurrence in Egypt” 2018),  
1226 24 (Laughlin et al. 1979), 25 (“WHO | Rift Valley Fever – Gambia” 2018), 26 (Centers for Disease Control  
1227 and Prevention (CDC) 1998), 27 (Woods et al. 2002), 28 (Centers for Disease Control and Prevention  
1228 (CDC) 2007), 29 (Jouan et al. 1988), 30 (Faye et al. 2007), 21 (Sow et al. 2014), 32 (Bob et al. 2017), 33  
1229 (Sissoko et al. 2009), 34 (Métras et al. 2016), 35 (Youssof et al. 2020), 36 (Centers for Disease Control  
1230 and Prevention (CDC) 2020), 37 (FAO 2017), 38 (Ahmad 2000), 39 (Sow et al. 2016), 40 (Centers for  
1231 Disease Control and Prevention (CDC) 1998), 41 (Nderitu et al. 2010), 42 (WHO 2018), 43 (Archer et al.  
1232 2013), 44 (Frame et al. 1970), 45 (Monath 1974), 46 (Myne et al. 2015), 47 (Khan et al. 2008), 48 (Assiri,  
1233 Al-Tawfiq, et al. 2013), 49 (Cauchemez et al. 2014), 50 (Virlogeux et al. 2016), 51 (Sha et al. 2017), 52  
1234 (Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al.  
1235 2019), 53 (Daubney, Hudson, and Garnham 1931), 54 (Francis and Magill 1935), 55 (Kitchen 1934), 56  
1236 (Findlay 1932), 57 (Sabin and Blumberg 1947), 58 (Smithburn and Mahaffy 1949), 59 (Mundel and Gear  
1237 1951), 60 (Hoogstraal et al. 1979), 61 (Ki 2015), 62 (Park et al. 2016), 63 (Gurley, Montgomery, Hossain,  
1238 Bell, et al. 2007), 64 (Bird et al. 2009), 65 (Lo Iacono et al. 2015), 66 (Brebán, Riou, and Fontanet 2013),  
1239 67 (Poletto et al. 2014), 68 (Chowell et al. 2014), 69 (Kucharski and Althaus 2015), 70 (Cauchemez et al.  
1240 2016)

1241  
1242  
1243  
1244  
1245




1248 **Figure S1. Spillover and reactive vaccination patterns for Lassa fever virus (LASV).** (A)  
 1249 Observed weekly Lassa fever spillover cases (grey bars) and estimated seasonal spillover rate  
 1250 (red line). (B) Annual number of spillovers over the past 5 years (red) and cumulative  
 1251 distribution of simulated annual spillovers from 1000 replicates (grey). (C) Median weekly  
 1252 simulated spillover and human-to-human Lassa fever cases. (D) Average weekly number of  
 1253 reactive campaigns triggered via spillover detection compared to the estimated seasonal  
 1254 spillover rate (red line).




1256 **Figure S2. Spillover and reactive vaccination patterns for Middle Eastern respiratory**  
1257 **virus (MERS-CoV).** (A) Observed weekly MERS spillover cases (grey bars) and estimated  
1258 seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red)  
1259 and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C)  
1260 Median weekly simulated spillover and human-to-human MERS cases. (D) Average weekly  
1261 number of reactive campaigns triggered via spillover detection compared to the estimated  
1262 seasonal spillover rate (red line).





1264 **Figure S3. Spillover and reactive vaccination patterns for Nipah virus (NiV).** (A) Observed  
 1265 weekly Nipah spillover cases (grey bars) and estimated seasonal spillover rate (red line). (B)  
 1266 Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated  
 1267 annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and  
 1268 human-to-human Nipah cases. (D) Average weekly number of reactive campaigns triggered via  
 1269 spillover detection compared to the estimated seasonal spillover rate (red line).



1271 **Figure S4. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV).**  
 1272 (A) Observed monthly RVF spillover cases by region. (B) Annual number of spillovers over the  
 1273 past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000  
 1274 replicates (grey). (C) Median weekly simulated spillover and human-to-human RVF cases. (D)  
 1275 Average weekly number of reactive campaigns triggered via spillover detection. Fitted  
 1276 seasonality is not shown for RVFV as it was for the other pathogens because seasonality was fit  
 1277 separately for each region.

1278 **SI Text.**

1279

1280 **1. Sensitivity analysis: Analysis of reactive vaccination scenarios**

1281

1282 In addition to our baseline reactive vaccination scenario, we examined the sensitivity of  
1283 vaccination impact to varying different scenario parameters: the threshold number of cases  
1284 needed to trigger a response, vaccination coverage in the general population, vaccination  
1285 coverage of healthcare workers (HCWs), time from the threshold trigger to the start of  
1286 vaccination, vaccine per exposure protection for one or two doses (PEP), and time delay from  
1287 vaccination to protection (see Table 2 for default, low, and high parameter values). In addition,  
1288 we examined the sensitivity of model results to the assumed or estimated value of  $R_0$  for each  
1289 pathogen (SI Text section 2), and the impact of defining different catchment areas for  
1290 vaccination (SI Text section 3). The results of the sensitivity analysis for MERS-CoV are  
1291 summarized in the main text (Figure 6).

1292

1293 As expected, lowering the number of cases required to trigger a reactive vaccination campaign  
1294 or increasing the percent of the population targeted for vaccination increased the number of  
1295 vaccine regimens required for each pathogen (Figures S5-S8). These parameter values had a  
1296 similar impact on the number of vaccine regimens needed to vaccinate HCWs (Figures S9-  
1297 S12). Higher  $R_0$  values also increased the required number of vaccine regimens needed as  
1298 higher human-to-human transmission increased the likelihood of the case threshold being  
1299 exceeded. However, this impact was fairly small for LASV and RVFV due to their low  $R_0$  values  
1300 (Figures S5,S8).

1301

1302 When vaccination impact was measured as the fraction of cases averted, the largest impact for  
1303 each pathogen was achieved by lowering the threshold number of cases needed to trigger a  
1304 reactive vaccination campaign (Figures 4A, S13A-15A). The second largest impact on the  
1305 fraction of cases averted for each pathogen besides RVFV was achieved by decreasing the  
1306 delay between a campaign being triggered and the start of vaccination (Figures 4A, S13A-  
1307 S14A). For RVFV, the 2nd largest fraction of cases could be averted by increasing vaccination  
1308 coverage in the general population or increasing vaccine PEP for a single dose vaccine (Figure  
1309 S15A). Although lowering the response threshold maximized the fraction of cases averted for  
1310 each pathogen, it did not maximize the number of cases averted per vaccine regimen  
1311 administered, because lowering the threshold increased the number of vaccine campaigns and  
1312 the required number of vaccine regimens (Figures S5-S8, 4B, S13B-S15B). For LASV, the  
1313 largest per regimen impact was achieved by minimizing the delay prior to vaccination (Figure  
1314 S13B). For NiV and RVFV, the largest per regimen impact was achieved by raising the  
1315 response threshold (Figures S14B-S15B).

1316

1317 For each pathogen (besides RVFV, which is not associated with nosocomial transmission)  
1318 vaccinating HCWs had a larger per regimen impact than vaccinating the general population  
1319 (Figures 4C, S13C-S14C). Reducing the delay prior to vaccination and increasing vaccine PEP  
1320 had the largest impact on the number of cases averted per HCW vaccinated (Figures 4C, S13C-  
1321 S14C). The number of cases averted was slightly lower under our high-coverage of HCWs

1322 scenario because the high coverage of vaccination among HCWs was paired with low coverage  
1323 among the general population (Figures 4A, S13A-S15A). However, this scenario would have  
1324 achieved the highest number of cases averted per total number of vaccine regimens  
1325 administered for LASV, MERS-CoV, and NiV.

1326

## 1327 **2. Sensitivity analysis: Impact of $R_0$**

1328

1329 All  $R_0$  values and uncertainty ranges used in our analysis were either drawn from the literature  
1330 or estimated from data (see Table 1 for parameter values and data sources). However,  $R_0$   
1331 estimates vary between studies and can also vary in space or time due to different  
1332 environmental conditions or differences in human contact networks. Therefore, we also tested  
1333 the sensitivity of our model results to lower and higher  $R_0$  values for each pathogen (for RVFV,  
1334 the default  $R_0=0$ , so only sensitivity to a higher value was examined). The number of total cases  
1335 increased with  $R_0$  for each pathogen, with the largest sensitivity observed for MERS-CoV  
1336 because the high estimate of  $R_0$  was close to 1 (Figure S16). There was also a large increase in  
1337 the number of vaccine regimens required to vaccinate either the general population or HCWs for  
1338 MERS-CoV at the higher  $R_0$  value, but the impact of  $R_0$  on the required number of vaccine  
1339 regimens was minimal for the other pathogens (Figures S17-S18). As a result, there were  
1340 minimal differences in the impact of vaccination under higher or lower  $R_0$  values for LASV, NiV,  
1341 or RVFV (Figures S19-S22). Vaccination averted both a greater magnitude and a higher fraction  
1342 of MERS cases as  $R_0$  increased (Figures S19-S20). In addition, the number of MERS cases  
1343 averted per vaccine regimen administered to the general population or to HCWs also increased  
1344 as  $R_0$  increased (Figures S21-S22). These results highlight the increasing potential  
1345 effectiveness for reactive vaccination as a control strategy as  $R_0$  approaches 1 and larger  
1346 outbreaks become more likely.

1347

## 1348 **3. Model limitations**

1349

1350 The goal of our analysis was to estimate vaccine stockpile needs and identify the most  
1351 important determinants of success for reactive vaccination of zoonotic emerging pathogens. We  
1352 modeled several different reactive vaccination strategies that are applicable to any zoonotic  
1353 emerging pathogen, and tested this framework for four pathogens with differing epidemiologies.  
1354 In addition, we explored the sensitivity of our results to different aspects of reactive vaccine  
1355 deployment, such as the coverage level, deployment delays, and vaccine per exposure  
1356 protection. However, there are some limitations to our approach that could affect these  
1357 estimates.

1358

1359 First, we have a relatively poor understanding of the epidemiology of most emerging zoonotic  
1360 pathogens, and data that could be used to try and elucidate the most important aspects of their  
1361 epidemiologies is limited. Here we examined the impact of reactive vaccination for four  
1362 pathogens with differing epidemiologies to try and capture how a range of epidemiological  
1363 parameters (e.g., spillover rates,  $R_0$ , etc.) affect vaccine stockpile requirements and the likely  
1364 impact of vaccination. But there are still uncertainties surrounding the epidemiology of these  
1365 pathogens that could affect the results of our analysis, such as the frequency of human-to-

1366 human transmission of MERS-CoV in community settings (Group and The WHO MERS-CoV  
1367 Research Group 2013), or the route of NiV spillover to humans during recent outbreaks in India  
1368 (Arunkumar et al. 2019). In addition, because no vaccines have been licensed for these  
1369 pathogens yet, we had to make assumptions about key vaccine parameters (e.g., number of  
1370 doses, time between vaccination and protection, and per exposure protection), based on the  
1371 current vaccine target product profiles (TPPs) for each pathogen. We also had to make  
1372 assumptions about the baseline reactive vaccination campaign parameter estimates such as  
1373 campaign response time and duration (and best-case and worst-case scenarios for our  
1374 sensitivity analysis). Assessing vaccine stockpile needs for newly emerged pathogens will  
1375 involve even more uncertainty as epidemiological knowledge is critically limited immediately  
1376 following emergence, as was demonstrated following the 2019 emergence of SARS-CoV-2 (Lee  
1377 et al. 2020; Tindale et al. 2020). Our modeling approach can be applied to newly emerged  
1378 zoonotic pathogens, but there will likely be a large amount of uncertainty regarding vaccine  
1379 stockpile needs and where vaccination campaigns are most likely to occur.

1380

1381 A second, related, limitation, is that the modeling framework is intended to be applicable for a  
1382 range of emerging zoonotic pathogens, and therefore cannot incorporate all of the specific  
1383 epidemiological details that might affect vaccine demand or impact for a particular pathogen.

1384

1385 Third, we only considered reported cases when estimating pathogen spillover rates and human-  
1386 to-human transmission because undiagnosed or unreported infections would not trigger an  
1387 outbreak response. For several of the pathogens considered, however, the majority of  
1388 infections--and even symptomatic cases--go unreported. A frequently cited study estimated that  
1389 LASV infects 100,000-300,000 and kills 5,000 people annually (McCormick et al. 1987), and  
1390 seroprevalence studies in several endemic areas indicate that spillover occurs much more  
1391 frequently than reported (Kernéis et al. 2009; O'Hearn et al. 2016; Gibb et al. 2017).

1392 Seroprevalence surveys for RVFV and MERS-CoV also indicate that these pathogens cause  
1393 many unreported infections in at least some subpopulations (Müller et al. 2015; Munyua et al.  
1394 2021; Bron et al. 2021). Therefore, our estimate of reactive vaccination impact does not take  
1395 into account the potential reduction in unobserved cases that would occur if at-risk populations  
1396 were vaccinated. Improved surveillance could address this issue and would likely increase the  
1397 frequency of reactive vaccination campaigns. This detection issue could also be partially  
1398 addressed by adjusting the case threshold for outbreak response to account for the case  
1399 detection probability, and then also adjusting vaccination impact to account for undetected  
1400 infections.

1401

1402 Next, because the extent of community transmission for each of the study pathogens is poorly  
1403 understood, we assumed that human-to-human transmission was limited to nosocomial  
1404 settings. Although this could result in an underestimate of vaccine demand, our model  
1405 simulations are consistent with epidemiological patterns observed to date (Figures S1-S4). We  
1406 also assumed that all nosocomial transmission involved transmission from patient to HCWs or  
1407 between HCWs and that there was no patient-to-patient or HCW-to-patient transmission.  
1408 Therefore our estimates of the impact of vaccinating HCWs represents the upper-bound on the

1409 effectiveness of this strategy as instances of patient-to-patient transmission would not be  
1410 prevented via this strategy.


1411  
1412 Another simplifying assumption of our model is that cases in one catchment area do not lead to  
1413 transmission or an outbreak outside of that catchment area. However, imported cases of these  
1414 pathogens have been reported. A MERS-CoV outbreak in South Korea derived from a spillover  
1415 event in the Middle East (Park et al. 2016), a NiV outbreak in Singapore derived from a spillover  
1416 event in Malaysia (Chan et al. 2002b), and cases of Lassa fever have been imported to Europe  
1417 (Overbosch et al. 2020). These types of events have been rare, and none of these documented  
1418 events resulted in an outbreak larger than the range of those that we simulated. Furthermore,  
1419 documented outbreaks involving pathogen spread to neighbouring catchment areas are  
1420 included in our datasets, and as such are to some extent captured in the current analysis. For  
1421 example, our datasets include Lassa fever cases in Benin derived from an outbreak in the  
1422 neighbouring adm2 located in Nigeria and RVFV outbreaks within multiple catchment areas of  
1423 Tanzania that likely resulted from the movement of livestock (ProMED-mail 2020; Bron et al.  
1424 2021). Therefore, our model already implicitly incorporates the possibility of spread between-  
1425 catchment areas, and although our model does not predict spillover cases occurring outside of  
1426 each pathogen's currently documented geographic distribution, the reactive vaccination  
1427 strategies we examined should also be applicable for responding to imported cases and their  
1428 associated outbreaks.

1429  
1430 Another limitation is that we had to make several simplifying assumptions regarding the  
1431 implementation of the reactive vaccination campaigns. One such simplification was assuming  
1432 that all vaccine doses (per regimen) were administered on the same day. This is likely an  
1433 unrealistic assumption for mass vaccination campaigns, particularly those that cover large  
1434 geographic areas. Relaxing this assumption would reduce the public health impact of reactive  
1435 vaccination in the same manner that delays in the start of the vaccination campaign did in our  
1436 analysis. Another simplification is that we did not consider any targeted vaccination strategies  
1437 besides targeting healthcare workers to limit nosocomial outbreaks or ring vaccination around  
1438 index cases. For the ring vaccination we calculated the number of index cases that would trigger  
1439 a ring vaccination response, but we did not model the impact of this response. Besides these  
1440 two strategies, there might be other targeted vaccination approaches that would require a  
1441 smaller vaccine stockpile than targeting the general population while still producing a substantial  
1442 public health impact. For example, in the case of RVFV, a potential vaccination strategy might  
1443 include targeting high-risk groups such as veterinarians, butchers, and livestock holders. One  
1444 reason we did not consider this strategy is because of the coarseness or absence of the data  
1445 available on these professions. While veterinarians only constitute a small proportion of the at-  
1446 risk population, their higher risk of acquiring infections could increase the impact of a campaign  
1447 that targeted them for vaccination. This could also increase the safety of those that are often at  
1448 the frontline of an outbreak response. Similar targeted strategies might be envisioned for camel  
1449 workers in areas where MERS-CoV is endemic in livestock, or individuals who collect or  
1450 consume date palm sap in India and Bangladesh (Dudas et al. 2018; Islam et al. 2016).


1451



1452 Finally, spillover cases were distributed over catchment areas representing 2nd administrative  
1453 districts (or hospitals within the 1st administrative units in our sensitivity analysis), irrespective of  
1454 the urban/rural nature of the catchment area. This may result in an overestimation of the  
1455 population at risk and thus the number of regimens needed. Simulating the spillover rates per  
1456 2nd administrative unit, instead of at the 1st administrative level, could improve the estimation of  
1457 reactive vaccine demand. However, the adm2 location of spillover cases were not available  
1458 most of the time.  
1459  
1460  
1461




1463 **Figure S5. Vaccine regimens required for Lassa fever virus (LASV).** The impact of varying  
1464 several model parameters on the number of vaccine regimens required to meet reactive  
1465 vaccination campaign targets. Base refers to the default scenario used in our main analysis.  
1466 See Table 2 for specific parameter values.  
1467  
1468




1470 **Figure S6. Vaccine regimens required for Middle Eastern respiratory virus (MERS-CoV).**  
1471 The impact of varying several model parameters on the number of vaccine regimens required to  
1472 meet reactive vaccination campaign targets. Base refers to the default scenario used in our  
1473 main analysis. See Table 2 for specific parameter values.


1474



1476 **Figure S7. Vaccine regimens required for Nipah virus (NiV).** The impact of varying several  
1477 model parameters on the number of vaccine regimens required to meet reactive vaccination  
1478 campaign targets. Base refers to the default scenario used in our main analysis. See Table 2 for  
1479 specific parameter values.




1481 **Figure S8. Vaccine regimens required for Rift Valley fever virus (RVFV).** The impact of  
1482 varying several model parameters on the number of vaccine regimens required to meet reactive  
1483 vaccination campaign targets. Base refers to the default scenario used in our main analysis.  
1484 See Table 2 for specific parameter values.




1486 **Figure S9. Vaccine regimens required to vaccinate healthcare workers for Lassa fever**  
1487 **virus (LASV).** The impact of varying several model parameters on the number of vaccine  
1488 regimens required to meet reactive vaccination campaign targets among healthcare workers  
1489 (HCWs). Base refers to the default scenario used in our main analysis. See Table 2 for specific  
1490 parameter values.







1492 **Figure S10. Vaccine regimens required to vaccinate healthcare workers for Middle**  
1493 **Eastern respiratory virus (MERS-CoV).** The impact of varying several model parameters on  
1494 the number of vaccine regimens required to meet reactive vaccination campaign targets among  
1495 healthcare workers (HCWs). Base refers to the default scenario used in our main analysis. See  
1496 Table 2 for specific parameter values.




1498 **Figure S11. Vaccine regimens required to vaccinate healthcare workers for Nipah virus**  
1499 **(NiV).** The impact of varying several model parameters on the number of vaccine regimens  
1500 required to meet reactive vaccination campaign targets among healthcare workers (HCWs).  
1501 Base refers to the default scenario used in our main analysis. See Table 2 for specific  
1502 parameter values.



1504 **Figure S12. Vaccine regimens required to vaccinate veterinarians for Rift Valley fever**  
1505 **virus (RVFV).** The impact of varying several model parameters on the number of vaccine  
1506 regimens required to meet reactive vaccination campaign targets among veterinarians (HCWs).  
1507 Base refers to the default scenario used in our main analysis. See Table 2 for specific  
1508 parameter values.




1510 **Figure S13. Vaccination impact sensitivity analysis for LASV.** Sensitivity of vaccination  
 1511 impact for LASV to variation in different campaign parameters expressed as (A) fraction of  
 1512 cases averted, (B) cases averted per 100,000 vaccinated in the general population, and (C)  
 1513 cases averted per 1,000 health care workers (HCWs) vaccinated.




1515 **Figure S14. Vaccination impact sensitivity analysis for NiV.** Sensitivity of vaccination impact  
 1516 for NiV to variation in different campaign parameters expressed as (A) fraction of cases averted,  
 1517 (B) cases averted per 100,000 vaccinated in the general population, and (C) cases averted per  
 1518 1,000 health care workers (HCWs) vaccinated.







1520 **Figure S15. Vaccination impact sensitivity analysis for RVFV.** Sensitivity of vaccination  
 1521 impact for RVFV to variation in different campaign parameters expressed as (A) fraction of  
 1522 cases averted, (B) cases averted per 100,000 vaccinated in the general population, and (C)  
 1523 cases averted per 1,000 health care workers (HCWs) vaccinated.




1525 **Figure S16. Number of cases under different  $R_0$  assumptions.**



1527 **Figure S17. Number of vaccine regimens required under different  $R_0$  assumptions.**




1529 **Figure S18. Number of vaccine regimens required for healthcare workers (HCWs) under**  
1530 **different  $R_0$  assumptions.**




1532 **Figure S19. Number of cases averted by vaccinating the general population under**  
1533 **different R<sub>0</sub> assumptions.**  
1534






1536 **Figure S20. Fraction of cases averted by vaccinating the general population under**  
1537 **different  $R_0$  assumptions.**  
1538



1540 **Figure S21. Number of cases averted per vaccine regimen administered to the general**  
1541 **population under different  $R_0$  assumptions.**  
1542



1544 **Figure S22. Number of cases averted per vaccine regimen administered to healthcare**  
1545 **workers (HCWs) under different  $R_0$  assumptions.**

### 1546 3. Analysis of different spillover and vaccination catchment areas

1547  
1548 In our analysis we estimated spillover rates for each pathogen at the 1st administrative level  
1549 (adm1). We then accounted for spatial clustering of cases below the adm1 level by associating  
1550 each simulated case with a catchment area. In the main analysis, catchment areas were defined  
1551 as the 2nd administrative units (adm2) within each adm1. For countries with no 2nd  
1552 administrative level, hospitals within an adm1 were treated as catchment areas (hospitals within  
1553 10 km were combined into a single catchment area). This catchment area definition produced  
1554 1570 catchment areas for LASV, 767 for MERS-CoV, 5076 for NiV and 2126 for RVFV. Here we  
1555 consider two alternative catchment area definitions: (1) treating all adm1 units as unique  
1556 catchment areas, and (2) treating all hospitals within adm1 units as unique catchment areas  
1557 (with hospitals <10km apart combined into a single catchment area). The adm1 catchment area  
1558 definition resulted in 214 catchment areas for LASV, 82 for MERS-CoV, 375 for NiV and 343 for  
1559 RVFV. The adm1 hospitals catchment area definition produced 1749 catchment areas for  
1560 LASV, 3138 for MERS-CoV, 10799 for NiV and 4722 for RVFV. Therefore the adm1 catchment  
1561 areas are larger than the adm2 catchment areas, while the adm1 hospitals catchment areas are  
1562 generally smaller than the adm2 catchment areas. Because spillover rates were estimated at  
1563 the adm1 level, spillovers within an adm1 unit were allocated via a multinomial distribution to all  
1564 hospital catchment areas within that adm1 unit, with a probability of  $1/(\# \text{ of catchment areas}$   
1565  $\text{ within adm1})$ .

1566  
1567 The number of spillover cases remained the same under the different catchment area  
1568 definitions, but the frequency, timing, and location of reactive vaccination campaigns were  
1569 shifted. Reactive vaccination campaigns tended to be triggered sooner during the transmission  
1570 season for adm1 catchment areas because these catchment areas covered a broader area and  
1571 larger population (Figures S23-S26). There were only minor differences in the timing of  
1572 vaccination campaigns between the adm2 and adm1 hospitals catchment areas (Figures S1-S4,  
1573 S27-S30). The geographic distribution of spillovers was less clustered for the larger adm1  
1574 catchment areas, but more finely distributed and clustered for the adm1 hospital catchment  
1575 areas, particularly in countries like South Africa and Madagascar with large 1st-level  
1576 administrative regions (Figures 2A, S31A-S32A). A similar geographic pattern was observed for  
1577 the location of reactive vaccination campaigns (Figures 2B, S31B-S32B).

1578  
1579 The total number of human-to-human cases did not differ by catchment area definition for any of  
1580 the pathogens (Figures 1A, S33A-S34A). The median number of reactive vaccination  
1581 campaigns was lower using adm1 catchment areas than adm2 catchment areas for MERS-CoV  
1582 (3; 95% PrI: 1-6 vs. 4; 95% PrI: 0-11) and RVFV (3; 95% PrI: 0-6 vs. 5; 95% PrI: 0-20) (Figures  
1583 1B, S33B). In contrast, the median number of reactive vaccination campaigns were higher using  
1584 adm1 catchment areas for LASV (3; 95% PrI: 1-6 vs. 0; 95% PrI: 0-20) and NiV (1; 95% PrI: 0-3  
1585 vs. 0; 95% PrI: 0-8). The frequency of years with no reactive vaccination campaigns was lower  
1586 using adm1 catchment areas compared to adm2 or adm1 hospital catchment areas for all four  
1587 pathogens. Both the median number of reactive vaccination campaigns and the frequency of  
1588 years with no campaigns were similar using adm1 hospital catchment areas compared to the

1589 baseline adm2 catchment areas, although the frequency of years with no campaigns was  
1590 slightly higher for the adm1 hospital catchment areas for all four pathogens (Figures 1B, 34B).


1591  
1592 The number of vaccine regimens required to cover the general population were significantly  
1593 higher using adm1 catchment areas versus adm2 or adm1 hospital catchment areas for  
1594 (Figures 1C, S33C-34C). For MERS-CoV, the median required number of regimens increased  
1595 from 286,259 (95% PrI: 0-855,099) for adm1 hospital catchment areas, to 1,242,922 (95% PrI:  
1596 0-4,062,010) for adm2 catchment areas, and 14,303,325 (95% PrI: 1,416,969) for adm1  
1597 catchment areas. For LASV, the median required number of regimens increased from 0 (95%  
1598 PrI: 0-4,452,966) for adm1 hospital catchment areas and 0 (95% PrI: 0-5,184,360) for adm2  
1599 catchment areas, to 11,603,802 (95% PrI: 2,953,628-25,277,594) for adm1 catchment areas.  
1600 The number of vaccine regimens needed to vaccinate healthcare workers (HCWs) was also  
1601 lowest for adm1 hospital catchment areas and highest for adm1 catchment areas (Figures 1C,  
1602 S33C-S34C).

1603  
1604 The total number of cases averted via vaccination for each pathogen was also lowest using  
1605 adm1 hospital catchment areas and highest using adm1 catchment areas (Figures 1D, S33D-  
1606 S34D). For MERS, the median number of cases averted increased from 2 (95% PrI: 0-60) for  
1607 adm1 hospital catchment areas, to 6 (95% PrI: 0-83) for adm2 catchment areas, and 77 (95%  
1608 PrI: 0-342) for adm1 catchment areas. For Lassa fever, the median number of cases averted  
1609 increased from 0 (95% PrI: 0-306) for adm1 hospital catchment areas and 0 (95% PrI: 0-357) for  
1610 adm2 catchment areas, to 101 (95% PrI: 3-771) for adm1 catchment areas. For RVF, the  
1611 median number of cases averted increased from 29 (95% PrI: 0-3,525) for adm1 hospital  
1612 catchment areas, to 43 (95% PrI: 0-5,826) for adm2 catchment areas, and 66 (95% PrI: 0-  
1613 2,451) for adm1 catchment areas. For Nipah, the median number of cases averted was 0 for  
1614 each catchment area definition, but the mean was highest for adm1 catchment areas. The total  
1615 number of cases averted via vaccination of HCWs was also lowest using adm1 hospital  
1616 catchment areas and highest using adm1 catchment areas (Figures 1D, S33D-S34D). For  
1617 example, for MERS, the median number of nosocomial cases averted increased from 1 (95%  
1618 PrI: 0-60) for adm1 hospital catchment areas, to 4 (95% PrI: 0-77) for adm2 catchment areas,  
1619 and 55 (95% PrI: 0-259) for adm1 catchment areas.


1620  
1621 Although the number of cases averted via reactive vaccination was highest using adm1  
1622 catchment areas, the number of cases averted per vaccine regimen administered was not  
1623 necessarily the highest under this scenario because the number of regimens required was also  
1624 higher using adm1 catchment areas. For MERS, the highest per regimen impact was achieved  
1625 using adm1 hospital catchment areas where a median of 0.75 (95% PrI: 0-18.10) cases were  
1626 averted per 100,000 vaccine regimens administered. In comparison, a median of 0.58 (95% PrI:  
1627 0.02-2.58) cases were averted per 100,000 vaccine regimens administered in adm1 hospital  
1628 catchment areas, and 0.49 (95% PrI: 0-5.21) cases were averted per 100,000 vaccine regimens  
1629 administered in adm2 catchment areas. The highest per regimen impact for RVF was also  
1630 achieved using adm1 hospital catchment areas, with a median of 3.18 cases averted per  
1631 100,000 vaccine regimens administered versus 2.86 (95% PrI: 0-349.78) using adm2 catchment  
1632 areas or 1.69 (95% PrI: 0-68.42) using adm1 catchment areas. For Lassa fever the per regimen

1633 impact was relatively consistent across different catchment areas, and for Nipah the median  
1634 impact per 100,000 vaccine regimens administered was 0 for adm2 or adm1 hospital catchment  
1635 areas and 0.01 (95% PrI: 0-11.17) for adm1 catchment areas. For MERS and Lassa fever, the  
1636 largest impact of vaccinating HCWs as measured on a per-regimen-administered basis, was  
1637 also achieved using adm1 hospital catchment areas. The per-regimen impact of vaccinating  
1638 HCWs was minimal for Nipah, just as it was for vaccinating the general population (although the  
1639 estimated per-regimen impact of vaccinating HCWs was higher than the impact of vaccinating  
1640 the general population).  
1641







1643 **Figure S23. Spillover and reactive vaccination patterns for Lassa fever virus (LASV)**  
 1644 **within adm1 catchment areas.** (A) Observed weekly Lassa fever spillover cases (grey bars)  
 1645 and estimated seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5  
 1646 years (red) and cumulative distribution of simulated annual spillovers from 1000 replicates  
 1647 (grey). (C) Median weekly simulated spillover and human-to-human Lassa fever cases. (D)  
 1648 Average weekly number of reactive campaigns triggered via spillover detection compared to the  
 1649 estimated seasonal spillover rate (red line).  
 1650




1652 **Figure S24. Spillover and reactive vaccination patterns for Middle Eastern respiratory**  
1653 **virus (MERS-CoV) within adm1 catchment areas.** (A) Observed weekly MERS spillover  
1654 cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of  
1655 spillovers over the past 5 years (red) and cumulative distribution of simulated annual spillovers  
1656 from 1000 replicates (grey). (C) Median weekly simulated spillover and human-to-human MERS  
1657 cases. (D) Average weekly number of reactive campaigns triggered via spillover detection  
1658 compared to the estimated seasonal spillover rate (red line).  
1659




1661 **Figure S25. Spillover and reactive vaccination patterns for Nipah virus (NiV) within adm1**  
 1662 **catchment areas.** (A) Observed weekly Nipah spillover cases (grey bars) and estimated  
 1663 seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red)  
 1664 and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C)  
 1665 Median weekly simulated spillover and human-to-human Nipah cases. (D) Average weekly  
 1666 number of reactive campaigns triggered via spillover detection compared to the estimated  
 1667 seasonal spillover rate (red line).  
 1668



1670 **Figure S26. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV)**  
 1671 **within adm1 catchment areas.** (A) Observed monthly RVF spillover cases by region. (B)  
 1672 Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated  
 1673 annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and  
 1674 human-to-human RVF cases. (D) Average weekly number of reactive campaigns triggered via  
 1675 spillover detection compared to the estimated seasonal spillover rate (red line).  
 1676




1678 **Figure S27. Spillover and reactive vaccination patterns for Lassa fever virus (LASV)**  
 1679 **within adm1 hospital catchment areas.** (A) Observed weekly Lassa fever spillover cases  
 1680 (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of spillovers  
 1681 over the past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000  
 1682 replicates (grey). (C) Median weekly simulated spillover and human-to-human Lassa fever  
 1683 cases. (D) Average weekly number of reactive campaigns triggered via spillover detection  
 1684 compared to the estimated seasonal spillover rate (red line).  
 1685




1687 **Figure S28. Spillover and reactive vaccination patterns for Middle Eastern respiratory**  
 1688 **virus (MERS-CoV) within adm1 hospital catchment areas.** (A) Observed weekly MERS  
 1689 spillover cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number  
 1690 of spillovers over the past 5 years (red) and cumulative distribution of simulated annual  
 1691 spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and human-to-  
 1692 human MERS cases. (D) Average weekly number of reactive campaigns triggered via spillover  
 1693 detection compared to the estimated seasonal spillover rate (red line).  
 1694







1696 **Figure S29. Spillover and reactive vaccination patterns for Nipah virus (NiV) within adm1**  
1697 **hospital catchment areas.** (A) Observed weekly Nipah spillover cases (grey bars) and  
1698 estimated seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5  
1699 years (red) and cumulative distribution of simulated annual spillovers from 1000 replicates  
1700 (grey). (C) Median weekly simulated spillover and human-to-human Nipah cases. (D) Average  
1701 weekly number of reactive campaigns triggered via spillover detection compared to the  
1702 estimated seasonal spillover rate (red line).  
1703




1705 **Figure S30. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV)**  
 1706 **within adm1 hospital catchment areas.** (A) Observed monthly RVFV spillover cases by region.  
 1707 (B) Annual number of spillovers over the past 5 years (red) and cumulative distribution of  
 1708 simulated annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover  
 1709 and human-to-human RVFV cases. (D) Average weekly number of reactive campaigns triggered  
 1710 via spillover detection compared to the estimated seasonal spillover rate (red line).  
 1711




1714 **Figure S31. Geographic distribution of spillover cases and reactive vaccination**  
1715 **campaigns for adm1 catchment areas. (A) Geographic distribution of the expected annual**  
1716 **number of spillover cases for each pathogen. (B) Probability that a campaign will be triggered.**



1719 **Figure S32. Geographic distribution of spillover cases and reactive vaccination**  
1720 **campaigns for adm1 hospital catchment areas. (A) Geographic distribution of the expected**  
1721 **annual number of spillover cases for each pathogen. (B) Proportion of time a campaign will be**  
1722 **triggered.**



1724 **Figure S33. Annual cases and reactive vaccination impacts for adm1 catchment areas.**  
 1725 (A) Annual number of spillover, human-to-human (H2H), and total cases for each pathogen  
 1726 across the entire study region. (B) Annual number of vaccine campaigns that will be triggered  
 1727 due to the outbreak threshold. (C) Number of vaccine regimens required per year for outbreak  
 1728 response when either the general population or healthcare workers (HCWs) only are targeted.  
 1729 (D) Annual number of cases averted via vaccination.  
 1730



1732 **Figure S34. Annual cases and reactive vaccination impacts for adm1 hospital-based**  
 1733 **catchment areas.** (A) Annual number of spillover, human-to-human (H2H), and total cases for  
 1734 each pathogen across the entire study region. (B) Annual number of vaccine campaigns that will  
 1735 be triggered due to the outbreak threshold. (C) Number of vaccine regimens required per year  
 1736 for outbreak response when either the general population or healthcare workers (HCWs) only  
 1737 are targeted. (D) Annual number of cases averted via vaccination.